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IN VIVO KINOME SCREEN REVEALS NON-CANONICAL CDK-DRIVEN METABOLIC
ADAPTATION IN BRAIN METASTASIS

Frank Joseph Lowery III, BS
Advisory Professor: Dihua Yu, MD, PhD

Brain metastasis, which frequently arises from breast cancer, lung cancer, melanoma, and
colorectal cancer, remains a severely unmet medical need and its incidence continues to rise
while treatment options remain palliative. To better understand the biology underlying its
aggressive, incurable nature, I performed an unbiased in vivo kinome screen to identify
potential driver kinases of experimental brain metastasis in a nude xenograft model using the
human breast cancer cell line MDA-MB-231. Several of the kinase pools led to decreased brain
metastasis-specific survival in nude mice, shortening survival time by up to 50% relative to
controls. Targeted next-generation sequencing (NGS) was performed to analyze pre- and postinjection MDA-MB-231 cells, thus identifying 31 kinases that were significantly enriched in
multiple animals. To validate the clinical relevance of these potential targets, kinase expression
was analyzed in a collection of 32 clinical breast cancer, lung cancer, and melanoma brain
metastases by RNA sequencing (RNA-seq); all but two of the kinases were expressed in brain
metastases from all three types of primary tumor. Based on its enrichment in vivo and high
expression in brain metastasis across cancer types, I chose to focus on PCTK1 as a potential
driver. PCTK1 is expressed during spermatogenesis and neuronal differentiation but reports of
its roles in cancer are limited. While overexpression of PCTK1 in MDA-MB-231 cells did not
affect proliferation under routine cell culture conditions, it led to a faster rate of brain metastasis
vii

growth and thereby decreased mouse survival time by 75%. The Cancer Genome Atlas (TCGA)
data analysis revealed a potential link between PCTK1 expression and glutamine metabolism
and I demonstrated that the growth advantage conferred by PCTK1 was due to increased
glutamine consumption by the cancer cells. Knockdown of PCTK1 in the brain metastatic
HCC1954Br breast cancer cell line increased mouse survival time in an experimental brain
metastasis model, indicating that PCTK1 may indeed represent a potential therapeutic target
for brain metastasis. In conclusion, this study identified PCTK1 as a novel driver of brain
metastasis and exposed a means of cancer cell survival in the nutrient-restricted brain.
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Chapter 1: Introduction
1.1 Breast Cancer
1.1.1 Breast cancer epidemiology
Breast cancer is a common and frequently deadly malignancy. In 2016, approximately
246,660 American women will be diagnosed with invasive breast cancer (IBC) and nearly
40,450 women will die of this disease. Breast cancer can occur in men as well, but the incidence
and mortality rates are 100 times lower than in women (1). These statistics actually represent
improvement over the last 30 years, as early detection and advances in treatment regimens
have resulted in the decline of age-adjusted death rates from a peak of greater than 33 deaths
per 100,000 women in 1989 to around 21 deaths per 100,000 today. However, it must not be
discounted that the gains in survival rates have largely been manifested in early-stage breast
cancer, while advanced breast cancer continues to be incurable.
Breast cancer incidence is similar among non-Hispanic white and black women in the
United States, although there is a large disparity in mortality rates, with white women at 21.9
deaths per 100,000 and black women at 31 (1). While the reasons for this disparity are
unknown, a partial explanation may come from the increased prevalence of the more lethal
triple-negative breast cancer (TNBC) within this group (2). Strikingly, Asian-American, HispanicAmerican, and Native American women show lower incidence of and mortality due to breast
cancer than non-Hispanic white and black women in the United States, although the effect on
mortality is almost entirely due to the decreased incidence. These numbers are exemplary of
the importance of both genetic and environmental factors in the risk of developing breast
cancer.

1

Figure 1. Estimated cancer deaths in the United States in 2016. Breast cancer is the
second-leading cause of death among in the United States, behind only lung cancer. Reprinted
with permission from American Cancer Society, Cancer Facts & Figures 2016.

2

Figure 2. Trends in cancer death rates among females in the United States through 2012.
Breast cancer mortality rates have declined since the early 1990s, as the advent of
mammograms and targeted therapies led to earlier detection and more effective treatment.
Rates are age-adjusted to the United States population in 2000. Reprinted with permission from
American Cancer Society, Cancer Facts & Figures 2016.

Breast cancer risk rises substantially with age, as both breast cancer incidence and
mortality increase after age 60 (3). This risk association with age is not exclusive, however.
While younger (<40 years old) women only account for 5% of IBC diagnoses (4), breast cancer
was the most common cause of cancer-related deaths in this population in 2011, according to
3

the latest available statistics. Additionally, breast cancer occurring before the age of 40 is more
likely to be associated with genetic mutations in breast cancer susceptibility genes BRCA1 and
BRCA2 and/or a family history of breast cancer. Therefore, while the majority of breast cancer
deaths occur after the age of 50, a substantial number of life-years lost to breast cancer are
from those diagnosed at earlier ages.
The differences in age-adjusted breast cancer risks have recently been the focus of a
public health controversy in the United States. Namely, while mammograms have been
demonstrated to enable earlier detection of breast cancer ((5)) and early detection is known to
be a key predictive factor in long-term survival, two leading organizations, the American Cancer
Society (ACS) and the US Preventive Services Task Force (USPSTF), have recommended that
women of average risk begin regular mammography-based screening at a later age (45 or 50,
respectively) instead of the previous guidelines suggesting that screening start at age 40 (6, 7).
These decisions were based upon the findings that low number of cancers detected in younger
women does not warrant the cost of regular screening, both in terms of health care expenses
and the emotional toll of false-positive tests. It will take some time for the results of this change
in policy to become apparent, but one would expect that breast cancer incidence (that is,
clinically detected breast cancer) may see a decrease in the population of women under 50
years old with a possible concomitant rise in breast cancer mortality rates for the same group.

4

Figure 3. Screening and adjuvant therapy have both decreased the incidence of breast
cancer over time. Comparison of models of breast cancer death rates among women age 3079 with or without inclusion of mammogram and/or adjuvant therapy (tamoxifen, chemotherapy,
or both) estimated the lives saved as 25 per 100,000 per year, compared to only 12 for either
factor alone. Note that the population considered here is women age 30-79, so the estimated
death rate from breast cancer is higher than in previous figures which included the whole female
population. Reprinted with permission from Berry DA, Cronin KA, Plevritis SK, Fryback DG,
Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Intervention Cancer,
& Collaborators Surveillance Modeling Network. “Effect of screening and adjuvant therapy on
mortality from breast cancer.” The New England Journal of Medicine. 2005 Oct
27;353(17):1784-92.

1.1.2 Breast cancer features and clinical characteristics
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The stages of breast cancer at diagnosis, which heavily impact treatment options and
prognosis, range from Stage 0 to Stage IV. This staging is determined by both the size and
spread of the primary tumor. Stage 0 represents carcinoma in situ, in which cancerous cells are
found in either the duct or lobe of the breast, but have not invaded into the surrounding tissue.
Stage I refers to primary tumors 2 cm or smaller, and, if any tumor cells are found in the nearby
lymph nodes, the clusters are 2 mm or less. Stage II encompasses tumors 0-5 cm that have
spread to 1-3 axillary lymph nodes, as well as those less than 2 cm that are not detected in the
lymph nodes. Stage III represents tumors of any size that have spread to more than 3 axillary
lymph nodes, as well as tumors greater than 5 cm that have spread to any lymph nodes.
Additionally, cancer that has spread to the skin of the breast or the chest wall is classified as
Stage III. Stage IV comprises breast cancer that has spread beyond the breast and lymph
nodes and metastasized to bone, lungs, liver, brain, or other organs. (3)

Table 1. Stage-specific breast cancer survival rates in women in the United States.
Stage

5-year relative survival rate

0

100%

I

100%

II

93%

III

72%

IV

22%

Adapted and reprinted with permission from American Cancer Society, Cancer Facts & Figures
2016.

Breast cancer is divided into three main clinical subtypes based on histological and
pathological criteria. These subtypes, along with disease stage, dictate the standard of care.
The major subtypes are luminal, basal, and HER2, which are classified according to the
6

expression of 3 cell surface proteins: estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2) (8). General characteristics are included in
Table 2.

Table 2. Clinical characteristics of breast cancer subtypes.
Molecular Subtype

Gene
expression
pattern

Luminal

HER2

Basal

High expression of
hormone receptors and
associated genes (luminal
A>luminal B)

High expression of
HER2 and other
genes in amplicon

High expression of
basal epithelial
genes, basal
cytokeratins

Low expression of
ER and associated
genes

Low expression of
ER and associated
genes
Low expression of
HER2

Clinical
features

~70% of invasive breast
cancers

~15% of invasive
breast cancers

~15% of invasive
breast cancers

ER/PR positive

ER/PR negative

Luminal B tend to be higher
histological grade than
luminal A

More likely to be
high grade and
node positive

Most ER/PR/HER2
negative (‘triple
negative,’ TNBC)

Some overexpress HER2
(luminal B)

Treatment
response and
outcome

Respond to endocrine
therapy (but response to
tamoxifen and aromatase
inhibitors may be different
for luminal A and luminal
B).
Response to chemotherapy
variable (greater in luminal
B than in luminal A).

BRCA1 dysfunction
(germline, sporadic)
Particularly common
in African-American
women

Respond to
trastuzumab
(Herceptin)
Respond to
anthracyclinebased
chemotherapy

No response to
endocrine therapy or
trastuzumab
(Herceptin)
Appear to be
sensitive to platinumbased chemotherapy
and PARP inhibitors

Generally poor
prognosis

7

Prognosis better for luminal
A than luminal B.

Generally poor
prognosis (but not
uniformly poor)
Modified and reprinted with permission from Schnitt SJ. “Classification and prognosis of
invasive breast cancer: from morphology to molecular taxonomy.” Modern Pathology. 2010
May;23 Suppl 2:S60-4.

While these molecular subtypes of breast cancer are based on a rather simplistic 3gene signature, even advanced analysis of a large data set of tumors by The Cancer Genome
Atlas (TCGA) Network, which incorporated genomic, transcriptomic, proteomic, and
epigenomic signatures, failed to tangibly improve upon these classifications (9). Other recent
studies in have delineated up to 10 separate subtypes (10), but this molecular gerrymandering
has not yet elucidated any new actionable theme within breast cancers, and instead has only
served to re-emphasize their heterogeneity. To further this point, the only genes commonly
mutated in >10% of all breast cancer were in TP53, PIK3CA, and GATA3; the only other gene
mutated in >10% of any subtype of breast cancer was MAP3K1 in luminal A (9).
The lack of clarity generated by these large-scale studies is likely based on the fact that
the broad subtypes represent breast cancers with different cells of origin, while the narrower
grouping is further subsetting the tumors beyond their originating cells (11). These narrow
groupings could hold promise in terms of identifying therapeutic responders and nonresponders, but it would require careful post-hoc analysis of well-designed clinical trials, and
the fact that such subtyping is transcriptome-dependent would necessitate the messenger RNA
(mRNA) profiling of trial subjects. However, as an example of this potential, the TCGA analysis
did identify 2 smaller subsets of TNBC that did not cluster with basal-like breast cancer: claudinlow and normal-like (9, 12). Claudin-low cancer is a subtype of TNBC that proliferates more
slowly than basal-like cancer (13); normal-like TNBC molecularly resembles normal breast and
is negative for cytokeratins 5 and 6 and the epidermal growth factor receptor (EGFR) (14). In a
8

small study, normal-like TNBC had a favorable prognosis compared to basal-like (14). If such
differential prognoses are true in larger trials, and immunohistochemically amenable markers
are identified beyond genetic signatures, it may allow for their regular employment in clinical
practice (15).

Figure 4. Breast cancer subtypes originate from cells of different stages of mammary
development. (left) Subpopulations of normal breast tissue and potential cells of origin for the
intrinsic subtypes of breast cancer; these cells may represent a stage of developmental arrest
for a tumor with an origin earlier in the differentiation hierarchy or, alternatively, transformation
of a cell type at one specific stage of development. (center) The various breast tumor subtypes
molecularly compared to subpopulations from normal breast tissue. (right) The defining
expression patterns of luminal, mesenchymal or claudin-low, and basal-like cells. Reprinted
with permission from Prat A & Perou CM. “Mammary development meets cancer genomics.”
Nature Medicine. 2009 Aug;15(8):842-4.
9

Choice of breast cancer therapy is dependent upon stage at diagnosis, subtype, and
previous treatments. It can consist of surgery to excise the primary tumor and conserve the
remainder of the breast in the case of small, localized tumors or extend to radical mastectomy
(removal of the whole breast) with neoadjuvant or adjuvant therapy (including radiotherapy,
chemotherapy, and/or targeted therapy). Radiotherapy is delivered locally in the case of earlystage breast cancer in hopes of ensuring that any residual cancer cells following surgical
resection of the tumor are killed, while chemotherapy is given in an attempt to kill unseen tumor
cells that may have spread to the bloodstream. Both chemotherapy and radiotherapy serve as
regular means of treatment for cancers that have invaded beyond the breast, whether to the
lymph nodes or to secondary organs.
In addition to these classic treatment strategies, targeted therapies may be used
depending on the breast cancer subtype. Targeted therapies seek to disrupt the pro-growth or
pro-survival pathways that imbue cancer cells with growth advantages, and they attempt to do
so in a way that is less toxic to normal cells than chemotherapy does. For ER-positive breast
cancer, endocrine therapy, either by targeting the estrogen receptor itself [as in tamoxifen, a
selective estrogen receptor modulator (SERM)] or perturbing the availability of its ligands
(aromatase inhibitors such as letrozole or exemestane), is frequently used in treatment at all
stages. Because proteins called kinases, which activate other downstream target proteins by
post-translational modification known as phosphorylation, frequently play pro-growth and prosurvival roles in cancer cell signaling, they serve as common targets of small molecule
inhibitors. One such inhibitor, the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib,
has recently been approved for treating advanced hormone receptor-positive breast cancer
(16). HER2-overexpressing breast cancers have a number of therapeutic options targeting the
receptor, including trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), and
lapatinib. Trastuzumab serves as the first-line therapeutic option, but the other therapies can
serve as backup options in case of cancer progression. TNBC is unfortunately defined by its
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lack of molecular targets for targeted therapy. However, it has exhibited higher rates of
pathological complete response (pCR) following neoadjuvant chemotherapy regimens (17) that
included platinum-based compounds or taxanes (18-20). Furthermore, TNBC frequently
exhibits defects in DNA repair proteins BRCA1 and BRCA2, and clinical trials attempting to
promote synthetic lethality by treating with inhibitors of the DNA repair protein poly-ADP ribose
polymerase (PARP) are ongoing (21, 22). Despite the existence and continued development of
these and other therapies, breast cancer that spreads to secondary sites remains incurable (3).
Like other cancers, genetic instability and its resulting heterogeneity are the primary
reasons why it tremendously difficult to treat breast cancer. In this vein, it is quite telling that the
most common mutations in breast cancer are to TP53, which encodes the protein p53,
nicknamed the “guardian of the genome.” Loss of function of this or other tumor suppressors,
such as BRCA1 or BRCA2, which are frequently mutated in hereditary breast cancer, allow
mutant cells that would otherwise either repair their DNA or die to instead continue proliferating,
creating daughter cells that are more and more genomically unstable and phenotypically
diverse. This genomic instability and its resulting biological heterogeneity make cancer cells
incredibly fit when exposed to the crucibles of evolutionary selective pressure, whether they
come in the form of differing tumor microenvironments throughout the body or therapeutic
agents targeting distinct mechanisms of tumor growth. It is due to this fact that unless the target
of a therapy is totally indispensable to cancer cells for survival, they will find a way survive
without it and become resistant.
The best example of the acquired resistance phenomenon in cancer is the use of
imatinib in chronic myelogenous leukemia (CML). CML arises from cancer cells with a single
translocation of chromosome 9 and 22 [t(9,22)] that causes the kinase domain of Abl to be
constitutively activated downstream of the breakpoint cluster region on chromosome 22 (BCRAbl). Imatinib targets this mutation-driven cell growth and has transformed the treatment of
CML, doubling its 5-year survival from 31% in the pre-imatinib era to 63% in 2011, and serving
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as the best clinical example of a targeted therapy in action. However, even in this best-case
scenario wherein a single gene translocation represents the driving agent of cancer, resistance
still occurs through a number of mechanisms. This situation has played out similarly in breast
cancer, where aromatase inhibitor treatment leads to mutations causing constitutive activation
of the estrogen receptor, and where HER2 targeting in HER2+ breast cancer can lead to
resistance to up to four available therapies. Cancer has thus far proved impossible to cure once
it is no longer confined within the primary site, when it is no longer amenable to surgical removal.
Even the best, most promising targeted therapies tried to date have ultimately fallen short in
the game of molecular whack-a-mole.

1.2 Metastasis
1.2.1 Clinical background
While the vast majority of cancer funding and public attention are directed towards the
treatment and prevention of primary cancer (23), the sad truth is that 90% of cancer mortality
is due to metastasis, the spread of cancer to secondary organ sites (24). In primary cancers
affecting organs related to reproduction (e.g., breast, ovary, or prostate), which are necessary
for propagation of the species but non-vital at an organismal level, metastasis is the cause of
nearly all cancer-related deaths. With few exceptions, which will be addressed later, metastatic
cancer represents a terminal diagnosis; to emphasize this point, metastatic cancer patient
advocates have begun referring to themselves as “lifers” (25, 26).
Metastasis is typically considered to be late event in cancer progression, but this is
highly dependent upon cancer type and the associated capabilities of screening and early
detection. Imaging-based methodologies, including magnetic resonance imaging (MRI),
computed tomography (CT), and positron-emission tomography (27), are useful in detecting
cancer earlier than was possible in the past, but limitations of these technologies mean that
tumors must usually reach a diameter of at least 4-7 mm for detection (28, 29). While a 5 mm
tumor seems small, a lesion of that size is expected to contain upwards of 1.25x107 cells (30).
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Given cancer’s enormous genomic instability and biological heterogeneity, 12 million cells are
more than capable of proving evolutionarily fit.
Varied methods of screening and detection as well the natural history of different types
of cancer are manifested in the stages at diagnosis of different cancers. For example, cancers
with either screening tests available and in regular practice (breast and prostate) or relative
ease of observation (melanoma) are more likely to be detected and diagnosed prior to stage
IV, with only 6% of breast cancer and 4% of prostate cancer and melanoma are diagnosed at
the metastatic stage. Conversely, cancer types where regular screening is either not performed
or patients are diagnosed late due to symptom confusion, e.g., cancers of the esophagus,
stomach, or small intestine, are often diagnosed at stage IV and carry a markedly poorer
prognosis. Indeed, this is evident in a comparison of 22 primary cancer types in the National
Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) database, which
shows that there is a strikingly negative correlation between the percentage of patients of a
given cancer type diagnosed at stage IV and 5-year survival. The fact that stage IV cancer
carries a worse prognosis is unsurprising, but that such a comparison yields an R2 value of 0.45
is almost shocking. Independent of tumor biology or therapy available for different types of
primary cancer, the presence of metastasis at the time of diagnosis in a subset of patients is
highly correlated with survival outcomes in the whole cohort.
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Figure 5. Negative correlation between percent of patients diagnosed with stage IV
cancer and the five-year survival of all patients of that tumor type. Linear regression
performed on data from SEER (SEER 18 2005-2011). Solid line represents the regression y =
-0.3956x + 42.66, R = 0.45. Dotted lines indicate 95% confidence interval. Tumor types
2

representing substantial departures from the line of best fit are indicated on the plot.

One of the most sobering implications put forth by this data is the sheer level of
determinism that currently exists between the presence of metastasis and the likelihood of
mortality due to said metastasis. If current therapies could significantly affect the long-term
survival of cancer patients with metastasis, no such linear relationship would be evident.
However, metastatic cancer is typically treatment-refractory, as it is composed of tumor cells
that have progressed and grown under the artificial selective pressure of chemo-, radio-, or
targeted therapy and/or the natural selective pressure the microenvironment of a secondary
organ. Therefore, metastasis represents a substantially different population of cancer cells than
the primary tumor from which it originated.
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The ending that befalls metastatic cancer patients is unimaginably painful. As the tumor
cells outcompete the resident cells comprising the body’s essential organ systems, patients
ultimately succumb to organ failure. This failure can be brought about by metastasis to the
bones, which first leads to risk of fracture due to structural erosion and later to suppression of
the body’s ability to maintain its hematopoietic and immune systems as the cancer cells
overtake the bone marrow (31, 32). The lungs are incredibly hardy and resilient, able to allow
for survival even when tumor burden reduces their capacity by up to 75% (with continuous
supplemental oxygen); however, when overtaken by metastasis they eventually cannot keep
up with the body’s need for oxygen. Patients may die due to lack of oxygen, lung infection, or
heart failure (33-35). Liver metastasis can be fatal when the liver parenchyma is replaced by
tumor tissue, preventing essential metabolic functions and leading to multi-organ system failure,
metabolic acidosis, renal insufficiency/renal failure, or total liver failure (36, 37). Brain
metastasis carries the worst prognosis; its lethality is attributed to neurological losses of
function, headache, seizure, cognitive or motor dysfunction, and coma (38, 39). In addition to
directly causing death, metastasis across cancer types can also increase the risk of infection,
heart failure, pain medicine overdose or other complications. Thus far, treatment is largely
palliative; there is little chance of long-term survival for those diagnosed with metastatic
disease. What it is it that makes this diagnosis so dramatically worse than primary cancer?
What exactly is so unique about metastasis that has made it such an insurmountable
challenge?

1.2.2 The biology of metastasis
One of the key concepts of metastasis was described in the seminal work “The
Distribution of Secondary Growths in Cancer of the Breast” by Stephen Paget, a 19th century
English surgeon (40). Paget observed the records of 735 women who had died of breast cancer,
and noted a strong preponderance of metastases to the liver and lungs. He looked at a further
244 lethal cases of gynecological cancer and noted again a high proportion of liver metastases.
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He examined the contemporary literature and found that metastasis to bone was also quite
common, and that only specific bones were affected. He reasoned that the preferential growth
of metastases at certain sites was due to interactions between the unique “seeds,” i.e., the
cancer cells, and a receptive “soil,” the anatomic location of successful metastasis, not to
random chance. This idea stood in stark contrast to the accepted wisdom of the time, which
held that patterns of metastatic spread were due to simple patterns of vascular flow. While his
work was at first rejected, Paget’s “seed and soil” hypothesis was rediscovered and validated
by Dr. Isaiah Fidler in the 1970s and 80s. Fidler’s experiments demonstrated that only rare
populations of cells within a tumor are capable of forming metastases (41), even when
introduced directly into the circulation (42). His studies further showed that site specificity was
not due to the circulation dynamics; even following the transplantation of different organs
subcutaneously or intramuscularly into recipient mice prior to intravenous (i.v.) injection of
tumor cells, thus normalizing the cancer cells’ access to the target, cancer cells maintained
their original organ tropism (43).
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Figure 6. The seed-and-soil nature of metastatic organotropism. Some common cancer
types are included with their most frequent sites of metastasis. Direction of arrows indicates
spread from primary to metastatic site. Reprinted with permission from Wikimedia Commons.
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As suggested previously, the process of metastasis represents an evolutionary
challenge to potentially metastatic cancer cells. Fortunately, the degree, diversity, and number
of these physical constraints on would-be metastatic cancer cells make the process
tremendously inefficient. For this reason, cancer cells capable of initiating metastases have
been likened to decathlon champions (44). A schematic of the steps required for the successful
initiation and formation of metastases, reprinted from (44), is included as Figure 7.

Figure 7. The metastatic cascade. Successful establishment and growth of metastasis at
secondary organ sites requires that cancer cells fulfill 10 evolutionarily challenging steps.
Reprinted with permission from Talmadge JE & Fidler IJ. “AACR Centennial Series: the biology
of cancer metastasis: historical perspective.” Cancer Research. 2010 Jul 15;70(14):5649-69.
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The initial steps of the metastatic cascade are common to all transformed cells that grow
beyond even a few millimeters in diameter (45). Following cell transformation, cells need to
obtain oxygen and nutrients to survive and meet their needs for energy consumption and
biomass generation. Due to the limits of oxygen diffusion through tissue, which can be as low
as 100 µm (46), any cells beyond this distance from existing blood vessels would be unable to
survive and proliferate (47, 48); for this reason tumors cannot grow larger than 2-3 mm without
an adequate blood supply (49). Dr. Judah Folkman first connected the presence of blood
vessels around growing tumors to tumoral release of a factor that would later be identified as
vascular endothelial growth factor (VEGF) (50). While the means by which tumors acquire their
blood supply has proven to be more varied than simply VEGF release (51, 52), the requirement
of an adequate blood supply to support tumor growth is recognized as one of cancer’s hallmarks
(45).
Even a well-vascularized tumor abundant in mutations does not usually pose a threat if
it remains stationary and confined to its site of origin (53), with the exception being tumors that
grow locally but produce deleterious effects due to their physical size interfering with normal
physiological functions (54). In fact, it is the distinction between invasiveness and noninvasiveness of tumors that determines a malignant or benign diagnosis. Dr. Lance Liotta
demonstrated that only malignant cancers are able to degrade their basement membrane (BM)
and invade into the surrounding vasculature (55). Later studies determined that the causative
agents in BM degradation and invasion were matrix metalloproteases 2 and 9 (MMP2/9) (56).
As an aside, in addition the tumor classifications of benign versus malignant, a classification of
“pre-malignant” refers to transformed cells that are more likely to become invasive over time
given the accumulation of additional genetic aberrations. Some cancers have relatively wellcharacterized evolutionary courses, whereby development of additional mutations can be
correlated with a progressive increase in malignancy; these characterizations are referred to as
Vogelgrams, after Bert Vogelstein who first used it to describe the sequential genetic changes
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and malignancy of colorectal cancer (CRC) in 1990 (57). The progression of increasing genomic
mutational events corresponding with increased malignancy can be observed in CRC and
cancers of the breast, prostate, esophagus, and cervix, among others, which are preceded by
the premalignant lesions colorectal adenoma, carcinoma in situ [ductal carcinoma in situ (DCIS)
or lobular carcinoma in situ], prostate intraepithelial neoplasia (PIN), Barrett’s esophagus, and
cervical dysplasia, respectively. However, detection of a pre-cancerous lesion with mutation X
does not guarantee the accumulation of subsequent mutations Y and Z or subsequent
progression to later stages in these diseases. This is important clinically, as overtreatment of
premalignancies such as DCIS and PIN and the associated loss of quality of life is one of the
main arguments against the earlier implementation of mammography for early detection of
breast cancer (58) and fanatical adherence to the results of prostate specific antigen (59)
screening for prostate cancer (60); the inability to determine which pre-cancers will progress to
invasive cancer mirrors the lack of predictability of which invasive cancers will metastasize.
Underscoring the evolution of both invasive cancer and metastasis is the fact that cancers are
genetically unstable and biologically heterogeneous, making it currently impossible to predict
which mutations will arise next in any tumor; even the father of the Vogelgram has deemed the
genetic mutations arising during cancer progression as stochastic (61).

Figure 8. Vogelgram of common genetic events occurring during development of CRC.
Ovals show oncogenic changes while rectangles show pathological state. Reprinted from

20

Wikimedia Commons with permission and based upon Fearon ER & Vogelstein B. “A genetic
model for colorectal tumorigenesis.” Cell. 1990 Jun 1;61(5):759-67.

The study of circulating tumor cells (CTCs) is becoming increasingly popular, as metaanalyses of large patient cohorts have demonstrated prognostic significance in the ability to
detect CTCs in the blood, with counts of >5 CTCs in 7.5 mL of blood yielding a negative
prognostic value in both breast and ovarian cancer (62, 63). Though the detection of high CTC
counts leads to a statistically significant hazard ratio (HR) of approximately 2 for overall
survival, this still implies that 33% of patients dying from disease will actually have low CTCs,
and that not all of those with high CTC counts are at risk. Thinking logically about the inefficiency
of the metastatic process, it is unsurprising that quantification of CTCs, which enter the
circulation relatively early in the metastatic cascade, would not be a perfect indication of
mortality due to metastasis. Following invasive cancer cells’ acquisition of the ability to degrade
the basement membrane and invade the vasculature, they are still unlikely to be able to survive
in the circulation, much less form metastases. A previous study demonstrated that <0.1% of
cancer cells injected directly into the bloodstream of mice remain viable 24 hours post-injection
(42). Even granting direct vascular access to tumor cells in humans by the use of peritoneal
shunts to alleviate the pain of malignant ascites of ovarian cancer did not result in death due to
metastasis (64). One of the key barriers to survival in the bloodstream is the requirement for
anoikis resistance. Anoikis is a form of programmed cell death resulting from loss of cell-toextracellular matrix (ECM) contact. Usually, cell-ECM contact provides cells with integrinmediated survival and growth signaling (65). Once this connection is lost, they will soon undergo
apoptosis. Successful metastatic tumor cells must overcome this invasion-control mechanism
in order to survive in the bloodstream, and one way to do so is by forming multicellular
aggregates. The cells of these tumor emboli can provide each other with the pro-survival signals
required to live in the absence of ECM contact (66). Additionally, cancer cell aggregation with
either other tumor cells or hematopoietic cells can protect tumor cells from shear stress in the
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blood (67, 68). Multiple experimental systems have shown the increased efficiency of
multicellular aggregates at seeding metastasis compared to the same number of single cells
(69, 70) and aggregates are detectable in patients (71-73). Recently, single-cell sequencing
has shown that the tumor cell aggregation occurs oligoclonally, suggesting that aggregates are
formed prior to tumor cell entry into the bloodstream (73).
The aggregation of tumor cells in the blood can also help the potentially metastatic tumor
cells negotiate the next challenge in the cascade, arresting within the vasculature of secondary
organs. The journey of tumor cells through the circulation ends one of two ways and both
involve getting stuck. One method is vascular occlusion, which occurs when a cancer cell or
cell cluster physically blocks the vessel in which it is traveling because its diameter exceeds
that of the vessel (74, 75). The second means of arrest within blood vessels is the adhesion to
vessel walls, a process similar to that employed by immune cell adhesion and displayed in
Figure 9 (76). Briefly, according to fluid dynamics, shear stress is higher near a boundary, in
this case the blood vessel wall. At that same point, the blood flow rate will be lower (77). So
while blood flowing through large vessels is traveling at a seemingly impossibly fast rate for
receptor-ligand binding to occur, cells that bounce close to the walls of the blood vessel actually
slow and are pushed toward the wall by shear forces. If the immune or tumor cells express cell
surface carbohydrates (frequently in the form of selectin ligands) compatible with those of the
endothelial cells (selectins), they begin to roll more slowly along the vessel wall. When tight
receptor-ligand binding occurs, such as that mediated by integrins, they firmly adhere to the
vessel wall (78). Interestingly, a study of brain metastasis revealed the top gene changed
between cancer cells metastatic to the brain versus other organ sites was ST6GALNAC5, which
encodes a molecule that mediates adhesion specifically to the brain vasculature (79).
Additionally, while tumor cells may adhere to the vascular walls through their own actions, this
binding may also be mediated by platelets, which express selectins and selectin ligands (74).
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Indeed, platelets have long been known to play pro-metastatic roles (80-82); their status as
adhesion mediators is key to successful metastasis.

Figure 9. The process employed by tumor cells in adhering to walls of the vasculature is
similar to that used by immune cells. In this process, cells traveling through the vasculature
at high rates of speed occasionally bump into the vessel walls. If cell surface ligands (boxed
with dashed line) meet their counter-receptors on endothelial cells, the cells will slow and begin
a rolling motion along the vessel wall. When the leukocyte or cancer cell binding avidity exceeds
the shear force of the blood flow, firm adhesion is achieved and the cells may be able to
extravasate. Reprinted with permission from Geng Y, Marshall, JR, & King MR.
“Glycomechanics of the metastatic cascade: tumor cell-endothelial cell interactions in the
circulation.” Annals of Biomedical Engineering. 2012 Apr;40(4):790-805.

Once cancer cells have disseminated into the vasculature of secondary organs, they
still need to be able extravasate into the organ parenchyma if they are to form true metastases.
This act of extravasation occurs in two steps: breach of the blood vessel wall, followed by the
physical migration out of the vessel. The migration out of the vessel is a simple matter of
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following chemokine gradients into the tissue (83); the chemokines present are tissue-specific
and thus demand different phenotypes from the tumor according to the organ involved, a
situation analogous to the extravasation of immune cells into target tissues (84). Using a chick
embryo chorioallantoic membrane model of metastasis, it was shown that human cancer cells
send small cytoplasmic actin-containing protrusions, termed invadopodia (85), through the
junctions of endothelial cells in order to breach the blood vessel wall enter into the surrounding
organs (86). This vascular breach can be enhanced through cancer cell secretion of VEGF or
tumor necrosis factor-α (TNF-α), which can weaken the endothelial cell tight junctions and/or
increase the subsequent tumor cell motility (87, 88).
Finally, followed extravasation, tumor cells have technically made it into the organ
parenchyma of a secondary organ site. If they are compatible with their new environment, they
may grow, develop their own blood supply, and even invade and spread further throughout the
body--metastasis of metastasis. However, this step in the metastatic cascade is actually the
most demanding of would-be secondary tumor. Upon dissemination and entry into the
secondary site, cancer cells still have to adapt to their new environment, which is highly unlikely
to be reminiscent of the setting of the primary tumor, and may include dramatically altered
nutrient resources and populations of resident cells that inhibit invasive cancer cells both
directly and indirectly. Additionally, as was true of growth at the primary site, if metastases are
to grow greater than a few millimeters in diameter, they will require their own blood supply.
Evidence of the exceptionally inefficient nature and the challenges posed at this step come from
multiple clinical and experimental observations. First, in an experimental model, less than
0.04% of cancer cells introduced into the circulation were able to form lung metastases, and it
was estimated that only around 20% of cells that were able to survive in the secondary organ
site went on to successfully form lung nodules (42). Xenograft studies in mice showed that
disseminated cancer cells that survived at secondary organ sites without forming detectable
metastases, when isolated from these non-metastatic organ sites and injected into recipient
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animals, were able to form spontaneous overt metastases (89). This so-called ‘dormancy’ is
one mechanism cancer cells may use to survive for long periods of time if the conditions in a
secondary organ are not optimal for growth, either in terms of availability of oxygen, nutrients,
or growth factors or due to active inhibition by host cells (e.g. immunosurveillance) (90).
Dormancy may also take two distinct forms: mass dormancy refers to those disseminated
micrometastases that either cannot obtain the blood supply or nutrition to grow beyond a few
millimeters, or are being held in check by immunosurveillance; cellular dormancy refers to
quiescent cells that have exited the cell cycle but remain viable (90).The concept of dormancy,
although difficult to model and study experimentally, also would account for clinical
observations on the timing of metastatic recurrence (91, 92). In breast cancer, it has been
shown in multiple large studies that there is a bimodal peak of metastatic recurrences, with
highest incidences at 18 months and 5 years following initial therapy (93). However, there
remains a non-zero risk of metastatic outgrowth more than 10 years following initial diagnosis,
and multiple studies have reported the appearance of overt metastases more than 20 years
following initial cancer diagnoses (92, 94-97). The role of immunosurveillance in suppressing
metastasis at the secondary site has been shown in humans following organ transplantation,
as organ recipients with no prior history of malignancy develop metastatic tumors in their grafted
organs (98-100). In each case, it has been shown that the organ donor had a primary cancer.
When the organ recipients were put on immunosuppressive drugs in order to prevent organ
rejection, the immunological suppression of these dormant cancer cells was abrogated and the
cells outgrew in the recipient, in several cases actually killing the organ recipient. In summary,
when cancer cells at secondary sites overcome whatever barriers are preventing their
outgrowth, through adaptation to the secondary site or changes to the site itself brought on by
such processes as aging, inflammation, or immunosuppression, they have achieved the
completion of the metastatic decathlon and can grow into overt metastases (101).
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Figure 10. Timing of metastatic recurrence in breast cancer. Left panel shows the hazard
ratio of metastatic recurrence (blue) plotted with local recurrence (red). Right panel shows that
the timing of metastatic recurrence is similar for bone (top, solid line), visceral organs (middle,
dotted line), and soft tissue (bottom, dashed line). X-axis shows months post-initial diagnosis,
Y-axis is hazard ratio. Reprinted with permission from Demicheli R, Biganzoli E, Boracchi P,
Greco M, & Retsky MW. “Recurrence dynamics does not depend on the recurrence site.” Breast
Cancer Research: BCR. 2008;10(5):R83.

It is evident from the rigorous functional demands of the metastatic cascade that the
evolutionary champions of such a process are unlikely to represent the same population of cells
from which they are derived, and the data have served to support this principle. It was
demonstrated that different clonal populations within a primary tumor have different abilities to
form metastasis (41), and that only a single metastatic clone (102, 103) or oligoclonal cluster
(73) is required to serve as the founder of a metastatic tumor. The disconcerting implication of
this fact is that even the best technologies interrogating genomic, transcriptomic, and proteomic
analyses of primary tumors are unlikely to yield predictive data on whether and where a primary
tumor could be expected to metastasize. Profiling of metastases, however, has shown that their
gene expression patterns differ from their associated primary tumors (104, 105) and even led
to some elucidation of the mediators of permissive seed and soil interactions hypothesized by
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Paget (79, 106). Coupled with the fact that metastases frequently arise as cancer recurrences,
following the development of therapeutic resistance, the disparate gene expression by
metastases and their associated primary tumors can also help explain the dismal prognosis of
metastasis: metastases can possess both de novo (107) and acquired resistance (108) to
therapies to which primary tumors and even other metastases respond (109-111). Interestingly,
in a case of the seed and soil theory at work, cells of the metastatic microenvironment can even
protect these secondary tumors from therapy, as is the case with astrocytes serving
chemoprotective roles during brain metastasis (112). Indeed, one of the only examples of
successful (albeit not curative) therapeutic targeting for metastasis involves not direct targeting
of tumor cells, but the more stable metastatic microenvironment in bone. Bone metastatic
cancer cells hijack the physiological bone remodeling process in order to obtain growth factors
from the bone matrix (113); remodeling involves the degradation of bone by osteoclasts and
the deposition of new bone by osteoblasts (114). In bone metastasis, cancer cells stimulate the
osteoclasts into excessive activity (113); the weakening of bones and associated risk of fracture
was noted by Paget as evidence for his seed and soil theory (40). Using therapeutic agents,
including bisphosphonates, denosumab, and dasatinib, that target the osteoclasts themselves
instead of the cancer cells has delayed skeletal-related events, such as fracture, associated
with bone metastasis and improved the quality of life of patients (27, 115). It must be noted,
however, that any differences observed in overall survival were marginal at best, suggesting
that bone metastatic tumor cells can find alternative means of survival even without the aid of
osteoclasts (116).
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Figure 11. Therapies against bone metastasis target the cells of the bone
microenvironment, not the cancer cells. Illustrated here is the vicious cycle of bone
metastasis and the steps of the process targeted by bone metastasis-targeted therapy. Left:
RANKL secreted by osteoblasts in response to stimulation by chemokines released from cancer
cells causes the maturation of osteoclasts, which degrade the bone matrix. Denosumab acts
as

an

antibody

against

RANKL,

thereby

decreasing

osteoclast

activity.

Center:

bisphosphonates act by inhibiting tumor cell adhesion to bone as well as directly enhancing
osteoclast apoptosis. Right: dasatinib is a small molecule inhibitor of SRC, which is key to
osteoclast proliferation and activity. Dasatinib may act through direct inhibition of cancer cells
or osteoclasts. Reprinted with permission from Fornier MN. “Denosumab: second chapter in
controlling bone metastases or a new book?” Journal of Clinical Oncology. 2010 Dec
10;28(35):5127-31.
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Recent breakthroughs in the technical ability to perform single-cell sequencing have
shed more light on the nature of metastasis by enabling modeling of the evolutionary nature of
metastasis. While population-level tumor genomic and transcriptomic profiling allowed
researchers to see that indeed primary tumors and metastatic tumors are different in terms of
overall gene expression (104, 105), they were unable to definitively provide answers to
questions on the nature of metastasis that have been debated for many years (117). Namely,
the questions of whether metastasis is a late-arising event in the natural history of a primary
tumor (following the linear progression/Vogelgram model of step-by-step acquisition of required
phenotypic traits) or dissemination occurs early in the evolutionary course of tumor
development followed by a period of dormancy or microenvironmental adaptation (parallel
progression). In experimental systems the answer has appeared to be more of the linear
progression model, as metastatic subclones increase within cancer cell lines (41) and can be
phenotypically selected in vivo for increased metastasis-forming capability (118, 119); however,
the possibility exists that this observation may be somewhat affected by the experimental
systems used (120). Single-cell sequencing has added the ability to interrogate the
accumulations of mutations over time and in space, as comparing individual cells within a
metastasis as well as between cells of different metastases and cells from metastases to cells
from primary tumors are all possible. These analyses have allowed direct observation of the
phenomenon reported by Fidler (41) that metastasis can result from the selection of pre-existing
subclones within a primary tumor and have served to strengthen the linear progression model
of metastasis (121-123). Nonetheless, tumor growth rate kinetic models lend support to the
idea of parallel progression (91, 124), as do clinical observations. Even in women diagnosed
with breast tumors less than 1 cm in diameter, node-negative, and metastasis-negative
(T1a,bN0M0) who undergo a mastectomy, dissemination may have already occurred by the
time of diagnosis, as there exists a 2% chance of breast cancer-specific mortality at 5 years
and a 5% chance at 10 years (125). Another study showed the probability of distant recurrence
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in 171 patients diagnosed with T1a,bN0M0 breast cancer and treated with mastectomy to be
4% (126). Further support for the parallel progression model comes from pancreatic cancer,
where clinical data has revealed early dissemination events (127) and experimental data has
shown that dissemination can shockingly precede overt primary cancer detection (128). Finally,
the existence of the clinical phenomenon of ‘cancer of unknown primary’ (CUP) serves to
bolster the parallel progression model, as in 3-5% of metastatic adenocarcinomas, a primary
tumor is unable to be identified, even at autopsy (129). In light of the available data, it would
seem most likely that the process of metastasis follows a hybrid of the linear/parallel
progression models (130), with metastasis initiated by dissemination of rare clones from within
the primary tumor, but with the acquisition of additional phenotypic traits upon reaching the
secondary site. The influence of the microenvironment on disseminated cancer cells should not
be understated, as the metastatic potential of cancer cells can be reversibly altered by
epigenetic modification (59, 131); this reversible modification can occur upon arrival at a
secondary site and before metastatic outgrowth (132).
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Figure 12. Metastasis arises from clonal populations of cells within the primary tumor.
These clonal populations can represent either major (Metastasis 1) or minor (Metastasis 2)
populations of cells within the primary tumor, and further evolution occurs following the
dissemination of cancer cells, resulting in metastasis that are distinct from their associated
primary tumors. Reprinted with permission from Caldas C. “Cancer sequencing unravels clonal
evolution.” Nature Biotechnology. 2012 May;30(5):408-10.

In light of the highly selective nature of the metastatic cascade, with each step
representing a potential barrier to success, it may serve as a useful reminder to consider those
conditions necessary for evolution by natural selection to occur. First, within a population there
must be some degree of phenotypic diversity. Second, members of a population must be able
to reproduce and pass down these heritable differences. Last, there must exist some limit to
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the ecosystem such that there is competition for finite resources (133). In the process of
metastasis all of these conditions are fulfilled, as cancer’s tremendous genomic instability and
biological heterogeneity lead to variation within a tumor (134), cell proliferation allows the
creation of daughter cells resembling their parent cell, and there is a finite limitation of
resources, both nutritional and volumetric, as both are limited within a tumor and within
secondary organ sites. Therefore, cancer metastasis is clearly an example of evolution; might
co-option of some evolutionary principles serve to enable both a better understanding of
metastasis and a better chance for successful intervention in the process (134)? One aspect
ripe for such examination is the stepwise nature of the metastatic cascade, which creates an
evolutionary scenario replete with population bottlenecks. Indeed, through single-cell genomic
analysis, it is possible to observe the results of such bottlenecks, as tumor cells with given
genomic patterns within the primary tumor drop out of populations observed in metastases (see
Figure 12 above) (121-123). These genomic observations represent strong evidence for the
selective nature of metastasis; but since natural selection works on the phenotypic level,
additional buttressing would come from evidence of enhanced abilities to perform functions
required for metastasis. Unfortunately, most modeling of the steps of metastasis is performed
in vitro (135, 136), leading to questions about the relevance or requirements of certain findings.
However, with the falling costs of sequencing (137), it is now possible to interrogate specific
aspects of the metastatic cascade in vivo at the single-cell level (138). For now, the best
examples of matching of genotype to phenotype in cancer progression come from the
population bottlenecks generated by drug treatment. Due to the genomic instability of cancer
cells, development of resistance to chemo- or targeted therapies is inevitable, as minor
subpopulations of cells exist pre-treatment with mutations that confer drug resistance. Following
development of resistance in the clinic (e.g., tumor progression while the patient is still receiving
therapy), it is possible to observe an increase in the allelic frequency of certain mutations; these
mutations may be in the genes coding the drug targets themselves or in other pathways
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involving drug efflux or apoptosis resistance (139-142). Recalling the principles of evolution,
organisms (or cells) with differential fitness in a given environment will be more evolutionarily
successful, i.e., become a more dominant population in successive generations. However, in a
closed system, the expression of new phenotypes is never free; acquisition of new traits
requires evolutionary tradeoffs. In this case of drug resistance this can come in the form of
adenosine triphosphate (ATP) costs to maintain drug efflux pumps; with up to 33% of cellular
ATP being spent on drug efflux, therapy-resistant cells will proliferate more slowly (143). The
concept of exploiting evolutionary tradeoffs has been proposed for application to treatment of
metastasis (144, 145); by identifying the Achilles’ heel exposed by high evolutionary costs at
steps during metastasis, it may be possible to use combination therapy to produce an
evolutionary double bind, a situation in which a metastasis is forced to fight a war on two fronts.
A depiction of such a therapy is shown below in Fig 13 (146). In this hypothetical situation,
Treatment 1 is targeted against one phenotype is to control a cancer population; the
development of resistance to that therapy incurs an evolutionary cost that can be exploited by
Treatment 2. However, as metastases are resistant to conventional therapies (111), intensive
and careful study is required in order to expose these potential targetable tradeoffs. Even
though metastasis represents evolutionary champions that are living in a state of cellular
anarchy, identification of the molecular details of non-negotiable convergent evolutionary
phenotypes that allow them to complete the metastatic cascade may enable identification of
double bind scenarios.
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Figure 13. Targeting evolutionary double binds for therapy against metastasis. Top graph
shows alternating appearance of populations resistant to Treatment 1 and sensitive to
Treatment 2, and vice versa. As resistance phenotype develops to one drug, remaining cells
incur evolutionary cost that is exploited by second treatment. Alternation of therapy can
continue over time. Bottom graph shows overall population density during alternating
treatments, as tumor re-growth would indicate necessity of switching back to the alternate
therapy. Modified and reprinted with permission from Enriquez-Navas PM, Wojtkowiak JW, &
Gatenby RA. “Application of Evolutionary Principles to Cancer Therapy.” Cancer Research.
2015 Nov 15;75(22):4675-80.
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1.3 Brain metastasis
1.3.1 Clinical overview of brain metastasis
In the United States, it is estimated that between 6% (147) and 14% (148) of all newly
diagnosed cancers will ultimately metastasize to the brain; based on the 1.7 million new
diagnoses of cancer expected in 2016 (1), between 100,000 and 240,000 cases can be
expected to eventually metastasize to the brain. These numbers represent a conservative
projection, for 3 major reasons: 1) autopsies of patients dying due to metastatic cancer are rare,
making comprehensive studies difficult and meaning that the apparent numbers seen thus far
may be a result of undersampling (149), 2) as improved systemic therapies have lengthened
the survival of patients with metastases to other organs, they may go on to develop brain
metastasis later (149), and 3) increased detection capability of clinical imaging modalities may
allow for the identification of brain metastases that in prior years would have gone unnoticed
(150). The primary cancers that most frequently metastasize to the brain are lung, breast,
melanoma, and colorectal, accounting for ~45%, ~15%, ~10%, and ~5% of brain metastases,
respectively. (149, 151)
Once brain metastasis has occurred, the survival outcomes are dismal. Left untreated,
the average survival is less than 2 months (152); palliative therapies including corticosteroids,
chemotherapy, and radiotherapy can extend survival, in the best case, to an average of less
than one year (153). When only a single brain metastatic tumor is detected, surgery or
radiosurgery can be performed; however, the effect of these therapies on survival is still
marginal, with life extended only a few months (151). Moreover, at the time of detection, multiple
brain metastases are formed in more than 80% of patients, disallowing surgery as a therapeutic
option (154, 155). As brain metastasis is almost universally chemoresistant, chemotherapy is
usually only used for treating systemic (non-brain) metastasis growing synchronously with the
brain metastasis or as salvage therapy (156, 157). Some primary tumors or tumor subtypes are
more responsive to therapy targeting specific molecular or functional pathways; while patients
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with known brain metastasis are typically excluded from trials for new agents, the enrollment of
some patients admitted to trials before diagnosis of brain metastasis has allowed on a small
window into the potential of targeted agents in brain metastasis, and it is generally not promising
(158). While some targeted therapies do indeed show brain activity and successfully make it
into the tumors, they are generally at lower concentrations than outside the brain (159), raising
the question of whether efficacious concentrations of the drugs are reached or maintained.
Further, these targeted therapies are designed against driver mutations in the primary tumors;
it is unclear how necessary they are for the biology of brain metastasis. What is unique about
the biology of the brain that makes for such a dismal prognosis in the setting of brain
metastasis?

Figure 14. Brain metastasis usually presents as multiple metastases. Magnetic resonance
imaging (MRI) showing numerous metastatic lesions throughout the cerebrum and cerebellum
of a woman with HER2-positive primary breast cancer. Reprinted with permission from
Ammannagari N, Ahmed S, Patel A, & Bravin EN. “Radiological response of brain metastases
to novel tyrosine kinase inhibitor lapatinib.” QJM. 2013 Sep;106(9):869-70.

1.3.2 Brain as a unique microenvironment for metastasis
The specialization of the brain to suit its functions as the processing and control center
for the body has led to the evolution of a number of features and safeguards not seen elsewhere
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in the body. As the primary role of the brain is to house and support the neurons that allow for
signals to be transmitted to and received from throughout the body, many of these features are
specifically designed to support and maintain neuronal function and integrity. The unique nature
of the brain microenvironment extends to its resident cell populations, structural composition,
blood flow, and nutrient availability. Each of these special characteristics represents a potential
challenge to would-be metastatic tumor cells; at the same time, cancer cells with the right
features to survive in such an environment can take advantage of the neuroprotective
environment in order to gain a foothold that has proven difficult to broach by current therapies.
When speaking of cancer, the most frequently cited brain-specific feature is the
presence of a blood-brain barrier (BBB) that separates the brain from the general circulation
(160). This ‘barrier’ is in reference to both form and function, as cells and molecules are
excluded from entry by physical obstruction, with the endothelial cells of the brain joined by tight
junctions, as well as by active efflux through transporters. The main purpose of this barrier is
the maintenance of homeostatic environment for neuronal function (161). Tight junctions, which
are composed of proteins including claudins, occludins, and zona occludens (ZO) proteins
(162), possess high electrical resistance (163), are surrounded by a thick basement membrane,
and supported on the brain-facing side of the BBB by pericytes. The high electrical resistance
prevents free diffusion of charged molecules through the BBB, while pericytes physically
support endothelial cells and promote their survival and maturation (164). Finally, astrocytic
endfeet form the final layer of the BBB. They express glucose transporters for allowing glucose
into the brain and P-glycoprotein for pumping drugs/neuroactive compounds out of the brain,
and can alter the tightness of the BBB in response to stresses such as hypoxia (165). Oxygen
and other lipophilic molecules can directly diffuse into the brain through the endothelial cell
membrane, and the brain’s high demand for oxygen means that at steady-state levels, the
partial pressure of oxygen (pO2) in the brain is only 35 mmHg (equates to 4.6% oxygen), which
maintains a continuous gradient of oxygen into the brain (166). Other required components of
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brain function, such as amino acids, are selectively admitted to the brain by specialized
transporters (167).

Figure 15. The BBB is formed by specialized cell types in the brain acting in concert.
Depicted here is a model of the BBB show its composition by different cell types. The inner
lumen (white) is formed by the endothelial cells (red), which are connected by tight junctions.
Pericytes (purple) partially cover the abluminal surface of the endothelial cells, which are
surrounded by a thick basement membrane (red dotted line). The entire unit is encircled by
astrocytes (blue); their endfeet express high levels of P-glycoprotein (as do endothelial cells
themselves) and actively exclude most drugs crossing into the brain. Most compounds making
it through the BBB are highly lipophilic, allowing them to diffuse across the endothelial cell
membrane into the brain. Modified and reprinted with permission from Steeg PS, Camphausen
KA, Smith QR. “Brain metastases as preventive and therapeutic targets.” Nature Reviews
Cancer. 2011 May;11(5):352-63.
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As cancer cells arrive and arrest in the vasculature of the brain, the first brain-specific
challenge that they encounter is the BBB. An intact physiological BBB prevents the entry of
cells into the brain; cells extravasating into the brain would therefore need to pass through the
endothelial cell layer either paracellularly (between the cells, through the tight junctions) or
transcellularly (through the endothelial cells themselves). While transcellular migration has
been observed in immune cell extravasation, only paracellular migration has been detected in
metastasis (168). Because tight junctions are composed of a variety of proteins, cancer cells
would need to be able to express several proteases in order to penetrate intact tight junctions
(169). Alternatively, these junctions can be destabilized by a variety of cytokines, chemokines,
and inflammatory mediators frequently expressed by cancer, including VEGF, basic fibroblast
growth factor (bFGF), transforming growth factor–β (TGF-β), interleukin-1β (IL-1β),TNF-α,
interferon-γ (IFN-γ ), CCL2, CXCL8, prostaglandin-endoperoxide synthase 2 (COX2), (79, 87,
88, 170); cancer cells can then secrete MMPs and other proteases in order to disrupt the BM,
as in metastasis to other sites. (87, 171).
After bypassing the BBB, cancer cells still have to cope with the unique nutrient
composition of the brain. Part of this challenge involves obtaining sufficient oxygen in a tissue
with a low pO , where there is a high degree of competition from neurons. Neurons solve the
2

problem of maintaining enough oxygen for mitochondrial respiration by never being farther than
40µm away from the nearest capillary (172); cancer cells in the brain converge upon this
phenotype as well, as imaging studies on experimental brain metastasis showed that cancer
cells stay in contact with blood vessels even following extravasation, until either VEGF-Amediated neoangiogenesis occurs or, more frequently in brain metastasis, the vasculature is
remodeled and co-opted by the cancer cells (75). One of the controversies in the field of brain
metastasis is the degree to which the BBB is disrupted following brain metastasis outgrowth.
While some studies have detected a heterogeneous permeability to chemotherapeutic agents
by brain metastases (173), others have shown that effects of brain metastasis on the leakiness
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of the BBB are cell line-dependent, with examples of both intact (174) or disrupted (175) BBB
in different contexts. In either case, this distinction is more than academic; if the BBB is not
functioning effectively around brain metastases, it might allow for delivery of efficacious doses
of therapeutics to brain tumors. Frustratingly, even in advanced brain metastases in which a
loss of functional integrity of the BBB would be expected, especially when metastases perform
vascular remodeling or neoangiogenesis (75, 176), the accumulation of a wide variety of
chemotherapeutic and small molecule targeted therapies still occurs at sub-optimal levels
(177).
A better explanation for therapeutic resistance of brain metastasis may lie not in the
hijacking of the brain’s vasculature by brain metastases, but in the co-option of astrocytes, the
brain’s essential support cells. Astrocytes in the physiological brain serve homeostatic functions
in support of the BBB (178, 179) as well as signaling and delivering nutrients directly to neurons
(180). Astrocytes’ homeostatic functions include prevention of cellular invasion of the brain
parenchyma; cancer cells breaching the BBB are soon met by astrocytes that release Fas
ligand (FasL) to trigger cancer cell apoptosis (181). Successful brain metastases win this
molecular arms race by expressing serpins, which prevent astrocytic release of FasL. After
evading elimination by astrocytes, cancer cells can take advantage of the protective benefits
that astrocytes usually afford neurons by a variety of mechanisms. Through gap junction
communication, astrocytes upregulate survival genes in brain metastatic cells, promoting
chemoresistance (182). This effect involves the engagement and upregulation of the endothelin
axis (112); antagonism of the endothelin axis chemosensitized tumor cells and significantly
extended survival in models experimental brain metastasis of lung and breast cancer (183). In
addition to gap junction communication, brain metastases can activate the pro-growth/survival
effects of astrocytes by secretion of IL-1β (184) or CCL2 (132), and have even been shown to
enhance the differentiation of neural progenitor cells into astrocytes (185).

40

On top of oxygen availability, the limited availability of nutrients in the brain makes for a
significant evolutionary bottleneck in the pathogenesis of brain metastasis. As the BBB
excludes most molecules from simply diffusing into the brain, specialized transporters are
necessary for their entry. These transporters exist for the import of glucose and some amino
acids; the high capacity of the endothelial cells glucose transporter GLUT-1 of 1420 nmol/min
x g tissue ensures the continuous import of glucose into the brain (186). The availability of
glucose, inability of other metabolic substrates, and high energy demands of the brain together
results in the brain’s utilization of 20% of the body’s glucose (187), which is evident by the
intense background signal of the brain in
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F-deoxyglucose (18-FDG) positron emission

tomography (27) (27) imaging (188). Astrocytes and neurons can both utilize glucose that
makes it into the brain, astrocytes through GLUT-1 and neurons through GLUT-3, which has a
higher glucose affinity (189). Once inside the cell, glucose can be used for either ATP synthesis
or the generation of other biomolecules. In either event, the first step of glucose metabolism is
the phosphorylation of glucose by hexokinase, generating glucose-6-phosphate (190). At this
point, the glucose-6-phosphate can either continue down the glycolysis pathway and be used
for ATP generation, or be shunted into the pentose phosphate pathway in order to generate
NADPH be used for the production of other biomolecules (190). Brain metastasis has been
observed to utilize both glycolysis and the pentose phosphate pathway. A study of human
breast cancer brain metastases, which at least in their early stages of colonization are still
restricted by a functional BBB, showed that the gene most highly upregulated relative to
unmatched primary tumors was hexokinase 2 (HK2), showing the importance of glycolysis for
intracerebral tumor growth and survival (191). A second study using experimental brain
metastasis models showed enhanced utilization of glucose in both glycolytic and pentose
phosphate pathways (192). That the same pathway was repeated by independent studies
serves to demonstrate that the physiological constraints imposed by the brain must be
overcome in order for successful metastasis.
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While it has been widely reported that due to the BBB, amino acids exist at lower levels
in the brain than the plasma, literature reports quantifying this phenomenon are scarce. Further,
the presence of the large neutral amino acid transporter 1 (LAT1) system enables the facilitated
diffusion of some amino acids (193), so quantification of the true concentration of amino acids
available to cells in the brain would be ideal. While these data are not available, an Alzheimer’s
disease study from 1990 did examine the cerebrospinal fluid (CSF) content of amino acids.
Comparison of the amino acid content in plasma and CSF of the healthy volunteers of that
study (n=11) was performed in Table 3, and revealed that the only amino acid found at
comparable levels in the general circulation and the CSF is glutamine, an important precursor
of the neurotransmitters glutamate and γ-aminobutyric acid (GABA) (194). This is suggestive
that utilization of glutamine may be an important functional constraint on successful brain
metastasis growth.
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Table 3. Amino acid content of human cerebrospinal fluid (CSF) and plasma.
Amino acid

CSF concentration (μM)

Plasma concentration (μM)

CSF/plasma ratio

Glutamic acid

42

62

0.68

Glutamine

505

500

1.01

Taurine

9

77

0.12

Alanine

34

319

0.11

Glycine

21

225

0.09

Isoleucine

5

58

0.09

Leucine

14

119

0.12

Methionine

5

22

0.23

Phenylalanine

9

54

0.17

Serine

30

109

0.28

Threonine

32

110

0.29

Tryptophan

0

41

0

Tyrosine

14

64

0.22

Valine

20

233

0.09

Arginine

23

87

0.26

Histidine

20

88

0.23

Lysine

25

181

0.14

Ornithine

7

69

0.1

The concentrations of amino acids in the CSF or plasma of healthy human volunteers are
shown. Most amino acids are relatively scarce in the brain, with the lone exception being
glutamine, which is found at levels equal to its plasma concentration. Table modified and
reprinted with permission from Basun H, Forssell LG, Almkvist O, Cowburn RF, Eklöf R,
Winblad B, & Wetterberg L. “Amino acid concentrations in cerebrospinal fluid and plasma in
Alzheimer's disease and healthy control subjects.” J Neural Transm Park Dis Dement Sect.
1990;2(4):295-304.
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In general, glutamine metabolism in the brain occurs in the form of a cycle rather than
as a unidirectional catabolic process. This series of reactions is known as the glutamineglutamate cycle, and it is responsible for maintaining the supply of the neurotransmitter
glutamate while also preventing constitutive neuronal hyperpolarization. Since glutamate can
be converted into glutamine, which is non-neuroactive, glutamine is the preferred form of the
compound when in the brain. The glutamine-glutamate cycle occurs when glutamate is
released into a glutamatergic synapse by the pre-synaptic neuron. Some glutamate binds to its
receptors on the post-synaptic neuron, but there is excess synaptic glutamate. This glutamate
is taken up by the surrounding astrocytes, which express high levels of excitatory amino acid
transporters (EAATs). Inside the astrocytes, the glutamate is metabolized by glutamine
synthetase, and processed into glutamine by the addition of an amino group. This glutamine is
then released by the astrocytes and taken up by pre-synaptic neurons. It is within pre-synaptic
neurons that glutaminolysis occurs, with glutaminase breaking down glutamine into its
constituents glutamate and ammonia. The newly synthesized glutamate is then packaged into
vesicles and released into the synapse, and the cycle proceeds again. Notably, cancers and
cancer cell lines have exhibited the potential to participate in the glutamine-glutamate cycle,
demonstrating a similar phenotype as neurons, with uptake of glutamine and release of
glutamate (195-198).
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Figure 16. The glutamine-glutamate cycle. Glutamine and glutamate are both present and
continuously being exchanged in normal brain physiology. Glutamate-containing vesicles within
the presynaptic neuron (blue) fuse to the neuronal cell membrane and are released into the
synapse. Some of this glutamate binds to glutamate receptors (mGluR, NMDAR, or AMPAR)
on the post-synaptic neuron (purple); the remainder is taken up by neighboring astrocytes via
their excitatory amino acid transporters (EAATs) in order to prevent neuronal hyperpolarization.
Within the astrocyte, glutamine synthetase converts ammonia and glutamate into glutamine,
which is then transported to the pre-synaptic neuron. Within the neuron, then glutamine is
converted to glutamate and the process is repeated. Modified and reprinted with permission
from Popoli M, Yan Z, McEwen BS, & Sanacora G. “The stressed synapse: the impact of stress
and glucocorticoids on glutamate transmission.” Nature Reviews Neuroscience. 2012
Jan;13(1):22-37
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Moreover, both brain metastasis and primary tumors have previously been reported to
exhibit altered glutamine metabolism (199). Specifically, they have both been shown to possess
an enhanced ability to utilize glutamine as both an energy source and as a precursor to cellular
building blocks, including purines, pyrimidines, and non-essential amino acids (200202). However, it remains unknown whether brain metastatic cells possess an intrinsic ability
to better utilize glutamine, or if this phenotype arises out of selection by the brain environment.
Finally, a mechanistic understanding of the regulation and cause of this enhanced glutamine
utilization is lacking, meaning that although the phenotype is biologically important and serves
as an evolutionary bottleneck for metastatic growth in the brain, it cannot currently serve as a
therapeutic target.

1.4 Hypothesis and specific aims
Brain metastasis represents an incredibly selective process that few cancer cells have
the capability of performing. While prior studies have focused on those genes that are most
differentially expressed between brain and non-brain metastases or between brain metastases
and primary tumors, here I propose that kinases may enhance key phenotypes that promote
brain metastasis growth. Identification of such kinases could elucidate the functional restraints
placed on metastatic cells arriving in the brain and potentially identify new avenues of
intervention.
To test this hypothesis, I propose the following two specific aims:
Aim 1: perform an in vivo functional genomics screen to identify kinases potentially
promoting the growth and formation of breast cancer brain metastasis.

Aim 2: Validate the top potential hit from this screen as functionally important in the
process of brain metastasis.
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Chapter 2: Materials and Methods
Kinase library preparation
The kinase open reading frame (ORF) library used to perform the in vivo kinome screen
was an expanded version of the library used in (203), containing 353 ORFs compared to 258
ORFS in the original library. The ORFs were contained in the retroviral vector pWZL-Neo-MyrFlag DEST, allowing expression of ORF sequences under control of the CMV promoter and
stable selection in target cells by G418.

Figure 17. Kinase ORF library is expressed in the pWZL-Neo-Myr-Flag-DEST retroviral
vector. Expression clones were generated by Gateway LR reactions, which inserted single
kinase sequences between the attR1 sites. Reprinted from Addgene.

In order to express the ORFs in a pooled format, five 96-well plates containing glycerol
stocks of the ORFs were divided into quadrants of 24 wells. Five microliters of each glycerol
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stock was inoculated into 3 mL of LB broth containing 100 µg/mL carbenicillin and grown at
37°C in a Forma Orbital Shaker (Thermo Fisher) at 250 rpm overnight. The following day, pools
of ORF clones were generated by combining groups of 24 clones, with each pool representing
one quadrant of each kinase library plate. Inoculum from each ORF clone (1 mL per clone; 24
mL per pool) was added to fresh LB media containing 100 µg/mL carbenicillin for a total volume
of 100 mL and grown for an additional 4 hours. Following this 4 hour growth period, the
inoculated LB broth for each pool was centrifuged at 4000 x g for 10 minutes at 4°C. Plasmid
DNA was isolated using a Qiagen Maxiprep kit according to the manufacturer’s protocol and
quantified using a NanoDrop ND-1000 spectrophotometer.

Cell lines and cell culture
Cell lines were cultured and maintained in Dulbecco's Modified Eagle Medium-Ham’s
Nutrient Mixture F-12 (DMEM/F12), which contains 17.5 mM glucose and 2 mM glutamine,
supplemented with 10% fetal bovine serum (FBS) and 100U/mL penicillin/streptomycin (Gibco).
Cells were regularly tested for mycoplasma contamination using the MycoAlert Mycoplasma
Detection Kit (Lonza). For later experiments involving Basal Medium Eagle (BME), cells were
cultured in BME, which contains 5.56 mM glucose, supplemented with 5% dialyzed FBS. The
amount of glutamine added varied by experiment. Cell lines used were obtained from American
Type Culture Collection (ATCC), and included Phoenix-AMPHO, MDA-MB-231, HCC1954, and
HEK293T.

MDA-MB-231.TdTomato

(231.TdTomato)

and

MDA-MB-231.luciferase.GFP

(231.luc.GFP) were generated by Gateway cloning and lentiviral transduction, followed by
fluorescence-associated cell sorting (FACS) for selection of fluorescent-positive cells.

Fluorescence-associated cell sorting (FACS)
FACS was performed in the Flow Cytometry and Cellular Imaging Core (UTMDACC) on
a Becton Dickinson FACS Aria II. Following trypsinization, cells were filtered through 35 μm cell
strainers into a 5 mL Falcon tube (Corning) to ensure a single cell suspension. Cells were
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analyzed on the FACS Aria II using the FITC and PE channels for 231.luc.GFP and
231.TdTomato cells, respectively; non-fluorescently labeled cells served as a negative control.
The top 10% of fluorescent cells were collected and cultured in 200U/mL penicillin/streptomycin
to eliminate any potential contamination acquired during FACS. Stably transfected target cells
were frozen in aliquots at low passage number.

Retroviral transfection
For retroviral production, the amphotropic Phoenix cell line (ATCC) was used. Phoenix
cells are derived from the HEK293T cell line and allow for packaging plasmid-free retroviral
production, due to gag-pol and viral envelope protein expression (204). Briefly, wells of a 6-well
plate were pre-coated with poly-L-lysine, following by the addition of 2.5 x 105 Phoenix cells to
each well for a confluency of approximately 70% the following day. Prior to transfection, media
was replaced with 1 mL of DMEM/F12 containing FBS. Separate dilutions of 1 µg plasmid DNA
and µL LipoD293 reagent (Signagen) were made in serum-free DMEM/F12 and mixed via
pipetting, according to the manufacturer’s protocol. LipoD293 reagent was then added to the
plasmid DNA and vortex-mixed. The liposomal-plasmid DNA mixture was allowed to incubate
at RT for 15 minutes, and then added drop-wise to the Phoenix cells. After 18 hours, 1.5 mL of
DMEM/F12 media with 10% FBS was added to each well. Two days post-transfection, the
retrovirus-containing media was aspirated into a 10 cc syringe fitted with an 18-gauge needle
and filtered through a 0.45 µm filter to remove Phoenix cell debris. Target cells were plated at
10% confluency in 6-well plates the day before virus collection, so that at the time of retroviral
infection they were 20% confluent. The virus-containing media, which totaled 2 mL due to
evaporation and dead volume in the syringe and filter, was added to target cells along with 8
mL of fresh DMEM/F12 with 10% FBS and 10 µL of 5 µg/mL polybrene. After 48 hours of
infection and expansion, G418 was added to the target cells to select for plasmid expression.
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Lentiviral transfection
Lentiviral transfection was performed similarly to retroviral transfection, except
HEK293T cells (293T) were used to produce lentivirus. Since 293T cells do not contain
packaging or envelope plasmids, exogenous packaging plasmid DNA (psPAX2 [Addgene
plasmid # 12260], gift from Didier Trono) and envelope plasmid DNA (pMD2.G [Addgene
plasmid # 12259], gift from Didier Trono) was included at the time of liposomal-DNA complex
formation, in a ratio of 4:3:1 (target DNA:psPAX2:pMD2.G). Additionally, as active cell division
is dispensable for lentiviral DNA to integrate into the cellular genome, the target cells were
plated at 25% confluence and were approaching 50% confluence on the day of infection.

Intracarotid injection
All animal procedures were approved by the UTMDACC Institutional Animal Care and
Usage Committee (IACUC). Accordingly, animals received humane care as per the Animal
Welfare Act and the NIH "Guide for the Care and Use of Laboratory Animals." For intracarotid
injection, 8-week-old female Swiss nude mice were purchased from the Department of
Experimental Radiation Oncology at UTMDACC. Mice were anesthetized with ketamine (90
mg/kg body weight) and xylazine (10 mg/kg body weight) and restrained supine on a glass
board. Their heads were secured to the board by placing a rubber band placed around the teeth
of the upper jaw. The surgical site was disinfected with Betadine and 70% ethanol, and a 1 cm
incision made slightly left of the midline, starting from the first mammary gland up into the neck
area. The trachea was then exposed by blunt dissection. Under a dissecting microscope, the
thin layer muscle was dissected in the carotid muscular triangle to expose the right common
carotid artery. The artery was then separated from the vagal nerve and jugular vein. A 5-0 silk
suture was placed under the proximal part of the common carotid artery and tied tightly to
prevent blood flow from the heart to the injection site. A second ligature was then placed under
the common carotid artery distal to the expected injection site and tied loosely. A 3-4 mm sterile
cotton ball was briefly soaked in Hank’s Buffered Saline Solution (HBSS) for lubrication and
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then placed under the artery between the two sutures to elevate the common carotid artery in
order to control the blood regurgitation from the distal part. Cell suspensions (100 μL of cancer
cells in HBSS) were drawn into a 1-cc insulin syringe without the formation or presence of
bubbles. Cells were then injected slowly and the needle retracted. The second ligature distal to
the injection site was quickly tied to prevent leakage of the injected cells, and the ends of the
silk ligatures trimmed. The skin of the surgical site was then stapled together and the animals
given subcutaneous buprenorphine to relieve pain. The animals were placed on a reusable
chemical heating pad until they regained consciousness. At the endpoint of the experiment,
mice were euthanized according to IACUC guidelines by CO2 asphyxiation followed by cervical
dislocation.

Mammary fat pad injections
For mammary fat pad injections, 8-week-old female Swiss nude mice were purchased
from the Department of Experimental Radiation Oncology at UTMDACC. Cancer cells were
prepared at 2x the intended injection concentration in HBSS, and then diluted 50:50 with
Matrigel and placed on ice. Mice were anesthetized with ketamine (90 mg/kg body weight) and
xylazine (10 mg/kg body weight). The cells were injected into the #3 mammary fat pads using
a 25G needle without incision. Injection efficiency was measured the day after injection using
in vivo imaging system (IVIS) analysis. At the endpoint of the experiment, mice were euthanized
according to IACUC guidelines by CO2 asphyxiation followed by cervical dislocation.

In vivo imaging system (IVIS) analysis
Luciferase-labeled tumor cell growth was monitored in vivo by IVIS. Imaging was
performed in the Small Animal Imaging Facility of UTMDACC on an IVIS-200 (Xenogen). Prior
to imaging, mice were injected intraperitoneally with 100 µL of D-luciferin potassium salt
(Biosynth) diluted at 15 mg/mL in phosphate-buffered saline (PBS) and anesthetized by
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isoflurane/O 5 minutes after D-luciferin injection. Luminescent images of tumor cells were
2

captured using the Living Image 3.2 software.

Recovery of cancer cells from in vivo tumors
For recovery of cells from in vivo brain metastases, tumor cells had to be harvested from
the brains of metastasis-bearing animals. Briefly, following euthanasia of a brain metastasisbearing mouse, the brain was placed in a petri dish on ice. A 10 cm cell culture dish was precoated by briefly rinsing with poly-L-lysine to support cell attachment, and a 100 μm cell strainer
placed in the dish with 5 mL complete media with 200U/mL penicillin/streptomycin. Forceps
were used to place the brain in the cell strainer, and the brain was homogenized using the
plunger of a 5 mL syringe, rinsing the strainer periodically with 1 mL of complete media with
200U/mL penicillin/streptomycin (up to 10 mL total) until the strainer was mostly cleared. The
brain homogenate was then cultured overnight at 37°C. The following day, the supernatant was
removed and added to a second poly-L-lysine coated dish, and fresh media with antibiotics was
added to the original dish. After 1-3 days, tumor cell colonies were visible through the floating
brain debris. Once colonies were numerous but still relatively low confluency, both primary and
secondary plates were trypsinized and combined into single 15 cm dish with normal cell culture
media. As cells approached 90% confluency, they were aliquoted and either frozen as a newly
established Br subline (HCC1954Br) or used for genomic DNA extraction in the kinase library
screen.

RNA isolation
Total RNA was isolated from cells or tissues using RNAzol RT (Molecular Research
Center, Inc.) according to manufacturer’s instructions. For direct RNA isolation from tissues,
brain were minced by with scalpels at time of animal sacrifice and stored at -80°C in RNA
stabilizing agent RNAlater (Sigma-Aldrich) until time of RNA isolation. RNA was quantified
using an ND-1000 spectrophotometer (NanoDrop).
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Complementary DNA (cDNA) synthesis
cDNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-rad), according
to manufacturer’s instructions. A mixture of random hexamers and oligo(dT) primers were used.

Genomic DNA (gDNA) extraction
gDNA was isolated using the DNEasy Blood & Tissue kit (Qiagen), according to
manufacturer’s instructions. DNEasy provides column and centrifugation-based DNA isolation.
DNA was quantified using an ND-1000 spectrophotometer (NanoDrop).

Polymerase chain reaction (PCR), Reverse transcriptase-PCR (RT-PCR), quantitative PCR
(qPCR), and qRT-PCR
PCR to analyze DNA or gene expression of gDNA or cDNA was performed one of the
following three ways:
1. presence/absence analysis: PCR of gDNA or RT-PCR of cDNA was performed on a
C1000 Touch thermal cycler (Bio-rad) using a Taq-based protocol. For kinase ORF PCR
analysis, the optimal annealing temperature was determined to be 52° C and the
extension time 4 minutes to accommodate the widest range of target sizes while
maintaining the specificity. Custom primer pairs for analyzing the kinase ORFs were
designed using VectorNTI software (Invitrogen) and ordered from Sigma and included
NeoF

(5’-GGATTGCACGCAGGTTCT-3’)

and

NeoR

(5’-

GCTTCAGTGACAACGTCGAG-3’) and KSPF (5’-CAAAGACGATGACGACAAGCA-3’)
and KSPR (5’-CTTCCTTCACGACATTCAACAGA-3’). PCR products were analyzed on
a standard 1% agarose DNA gel using ethidium bromide for ultraviolet (UV)
visualization.
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2. TaqMan: validated, human-specific, FAM-labeled TaqMan gene expression arrays were
purchased from Thermo Fisher. Probes used were CDK16 (Hs00178837_m1), GLS
(Hs00248163_m1), GLS2 (Hs00998733_m1), GFPT1 (Hs00899865_m1), and 18S-VIC
(4310893E). Due to its labeling with the fluorophore VIC instead of FAM, the primer
assay against 18S ribosomal RNA (18S-VIC) could be included in each well as an
internal control. qRT-PCR was performed on a StepOne Plus instrument (Applied
Biosystems) using KAPA PROBE FAST reagents (KAPA). Results were analyzed using
StepOne software and data were normalized to 18S signal.
3. SYBR Green: the same primer pairs as in “presence/absence analysis” above were
used. KAPA SYBR FAST reagents were used to perform qPCR on a StepOne Plus
instrument. Cycle threshold (Ct) values were calculated for kinase ORF amplification
and used to establish sample-specific PCR conditions required to obtain satisfactory
quantities of DNA for sequencing.

TOPO cloning
TOPO cloning was performed using a TOPO TA Cloning kit (Thermo Fisher), according
to manufacturer’s instructions. PCR products with A-overhangs, resulting from Taq-based
amplification, were subcloned into pCR-4-TOPO vectors and transformed into competent E.
coli. Transformed E. coli were inoculated into LB media and minipreps (Qiagen) were
performed. The resulting DNA was Sanger sequenced by the DNA Analysis Core (UTMDACC)
from pCR-4-TOPO-specific primers M13F (5’-GTAAAACGACGGCCAG-3’) and M13R (5’TCACACAGGAAACAGCTATGAC-3’). The sequences were then analyzed by the National
Library of Medicine’s Basic Local Alignment Search Tool (BLAST).

shRNA
shRNA-encoding plasmids expressed in the lentiviral pGIPZ vector were obtained from
the shRNA and ORFeome Core at UTMDACC, which distributes shRNA from GE-Dharmacon.
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The shRNAs used to target PCTK1 were clones V2LHS_202028, V2LHS_59072,
V3LHS_310893, V3LHS_310895, and V3LHS_310898, which are referred to ordinally as
shPCTK1-1, shPCTK1-2, shPCTK1-3, shPCTK1-4, and shPCTK1-5 for the remainder of this
dissertation. Stable vector-expressing cancer cells were selected both by puromycin resistance
and FACS sorting for GFP positivity, as both selective markers are encoded by the vector.
Knockdown efficiency was assayed at the RNA and protein levels by qRT-PCR and western
blotting,

respectively.

Next-generation sequencing (NGS) of kinome screen samples
gDNA from tumor cells recovered from in vivo brain metastases was amplified by PCR
using kinase vector-specific primers KSPF (5’-CAAAGACGATGACGACAAGCA-3’) and KSPR
(5’-CTTCCTTCACGACATTCAACAGA-3’). The number of PCR cycles required to amplify the
minimum amount of DNA required for NGS barcoding was empirically determined by SYBR
Green-based qPCR. Following kinase vector-specific amplification, column-based purification
of PCR products was performed using MinElute columns (Qiagen). DNA barcoding, adapter
ligation, and library preparation were performed using the NEXTflex DNA Sequencing Kit (Bioo
Scientific) according to the manufacturer’s instructions, with unique barcodes added to each in
vivo sample. The resulting barcoded DNA libraries were analyzed by a MiSeq instrument
(Illumina) using 150-base pair (bp), paired-end (PE) sequencing. Reads were normalized to the
total total reads for each barcode, such that each in vivo sample had equal representation using
MiSeq Reporter. Fastq files from Illumina paired-end sequencing were mapped to human
transcriptome

version

hg19

index.shtml).

Mapped

reads

using

tophat2

(https://ccb.jhu.edu/software/tophat/

were converted to bedGraph files

using

HOMER

(http://homer.salk.edu/homer/). For each kinase in each pool of the screen, the expression was
estimated by collecting all bedGraph reads falling inside the gene boundaries (based on refseq
gene definitions, available at http://hgdownload.soe.ucsc.edu/downloads.html).
55

RNA sequencing (RNA-seq) of human brain metastases
The RNA-seq data presented about gene expression within human brain metastases
was obtained via a collaboration with Drs. Jodi Saunus and Sunil Lakhani at the University of
Queensland, and the methods used for RNA-seq are published (205). Briefly, RNA-seq was
performed on 32 human brain metastases. RNA was extracted from fresh-frozen brain
metastasis surgical samples using the Qiagen AllPrep Kit, according to the manufacturer’s
instructions, and quantified using a Bioanalyser (Agilent). From their publication:
The protocol for Ribosomal depletion and RNA library construction was
performed on 1 µg total RNA from each sample, using TruSeq Stranded Total RNA kit
with Ribo-Zero Human/Mouse/Rat Set A (Illumina, cat. no. RS-122-2201). Libraries
were prepared according to the manufacturer's protocol (TruSeq Stranded Total RNA
Sample Prep Guide), with minor modifications to the fragmentation time (0 min
fragmentation was used to increase the insert length). The libraries were quality
checked and quantified using the Bioanalyser High Sensitivity DNA kit (Agilent).
All the RNA libraries were indexed, allowing multiplexed sequencing. Prior to onboard cluster generation and sequencing run, the pooled library was denatured by using
0.1 N NaOH and diluted to the required concentration (7 pM). Libraries were sequenced
as 100 bp paired-end reads on the Illumina HiSeq 2000. RNA data were analysed using
RSEM [7] and a normal expected count was used for expression values (using TMM
normalization in the edgeR package), which was then transformed to normalized
counts/million.
From Saunus et al (2015), Integrated genomic and transcriptomic analysis of human brain
metastases identifies alterations of potential clinical significance. J. Pathol., 237: 363–378. doi:
10.1002/path.4583. Reprinted with permission
Hard agar assay
In brief, 1 mL of DMEM containing 23% FBS and 0.6% agar (Lonza) was plated into
individual wells of 24-well plates (BD Biosciences). Cancer cells were trypsinized and
resuspended in DMEM containing 10% FBS. The resulting cell mixture was then passaged
through a 40-μm cell strainer (BD Biosciences) to generate a single-cell suspension. Cells were
resuspended at a density of 4000 cells/well in 1 mL of DMEM containing 23% FBS and 0.9%
agar. This cell-containing mixture was then pipetted gently over the bottom layer of agar (0.6%)
in the wells. The numbers and diameters of tumor colonies were calculated using a microscope
when the tumor colonies became visible, and the experiment was terminated after 60 days.
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Western blot analysis
Total cell lysates were obtained by resuspending cell pellets in immunoprecipitation (IP)
lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM beta-glycerolphosphate, 1 mM sodium orthovanadate, 1
mM PMSF, and protease inhibitor cocktail). Following addition of lysis buffer, lysates were
sonicated or passed through syringe with 22G needle 15 times followed by centrifugation. The
supernatant was transferred to a new tube, and protein concentration was determined by BCA
protein Assay Kit (Pierce), using known amounts of bovine serum albumin (BSA) to standardize
protein concentration. Cell lysates containing equal amounts (20-40µg, depending on
experiment) of protein were subjected to electrophoresis using sodium dodecosulfatepolyacrylamide gel elecotrophoresis (SDS-PAGE) and transferred to polyvinyldifluoride (PVDF)
membranes (Bio-Rad). PBS-Tween (PBST) was prepared as 0.1% (v/v) of Tween 20 in PBS.
Membranes were blocked with 5% milk PBST for 30-60 minutes at room temperature, followed
by primary antibody incubation overnight at 4°C. After three washes with PBST (5 minutes
each), membranes were incubated with HRP-conjugated secondary antibody (in 5% milk in
PBST) for 60 minutes at room temperature followed by three 5-minute washes with PBST, and
signal was detected by enhanced chemiluminescence (ECL) (Amersham) per the
manufacturer’s instructions. Antibodies used were PCTK1: rabbit anti-human CDK16, clone
HPA001366 (Sigma) and mouse anti-β-actin, clone AC-74 (Sigma)

Invasion
Transwell invasion assay was performed as previously described, with some
modifications (206). 15 μL of Matrigel (Corning) diluted 1:4 in PBS was added to the top
chamber of a 24-well transwell plate (Millipore). After Matrigel polymerization, the bottom
chambers were filled with 600 µL DMEM/F12 medium containing 10% FBS. The top chambers
were seeded with 5×104 cancer cells per well in 200 µL serum-free medium. After 24 hours,
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the experiment was terminated by scraping remaining cells off of the top chamber with a cotton
swab. Invaded cells were fixed in 4% paraformaldehyde and stained with 0.05% Crystal Violet.
Images were taken using an Olympus digital microscope and invading cells were counted
manually.

The

assays

were

performed

in

technical

and

biological

triplicate.

Migration
Transwell migration assay was performed as previously described, with some
modifications (206). The top chambers of a 24-well transwell plate (Millipore) were seeded with
3×104 cancer cells in 200 µL DMEM/F12 serum-free medium per well.

Then, 300 µL

DMEM/F12 medium containing 10% FBS was added to the bottom chamber. After 18 hours,
the experiment was terminated by scraping remaining cells off of the top chamber with a cotton
swab. Migrated cells were fixed in 4% paraformaldehyde and stained with 0.05% Crystal Violet.
Images were taken using an Olympus digital microscope and invading cells were counted
manually. The assays were performed in technical and biological triplicate.

Glutamine uptake and metabolite tracing/mass spectrometry (MS)
For experiments measuring rates of glutamine uptake and glutamate release over time,
samples were analyzed on a 2900D Biochemistry Analyzer (YSI). MassLynx software version
4.1 was used for data acquisition and analysis of glutamate and glutamine. Spectra of enriched
peaks were compared against reference spectra.

Immunohistochemistry (IHC)
IHC staining of PCTK1 on formalin-fixed, paraffin-embedded samples was performed
using rabbit anti-human CDK16, clone HPA001366 (Sigma). Briefly, slides were
deparaffinized by heating on a slide warmer for 20 minutes, followed by rehydration via a
series of 3-minute wash steps. Slides were submerged in xylene 2x, 100% ethanol 2x, 90%
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ethanol 1x, 80% ethanol 1x, and 70% ethanol 1x, and transferred to running water to rinse.
Heat-induced antigen retrieval was then performed using sodium citrate buffer, pH 6.0, in a
pressure cooker for 10 minutes. Blocking of non-specific epitope binding was achieved with
Protein Block (Dako). Primary antibody incubation was performed overnight at 4°C, at an
empirically determined dilution of 1:100 in Antibody Diluent (Dako). The next day, slides were
incubated for 15 in 0.3% H2O2 in Tris-buffered saline (TBS) to quench their endogenous
peroxidase activity. Secondary antibody staining was then performed using the Polink-2 HRP
Plus Rabbit DAB system (GBI) according to manufacturer’s protocol, except TBS and TBSTween (TBST) were used in place of PBS and PBST, respectively. Following secondary
antibody incubation and chromogen development, slides were counterstained with
hematoxylin, dehydrated, and mounted using organic mounting media.
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Chapter 3: Kinome Screen
To test whether heretofore unknown kinases may indeed be drivers of brain metastasis,
we set out to perform an unbiased in vivo screen. MDA-MB-231 cells were selected as the cell
background for this screen because they were originally derived from the pleural effusion of a
patient with claudin-low TNBC, and TNBC has the highest relative rate of brain metastasis
among breast cancer subtypes. First, pools of retroviral constructs were used to infect MDAMB-231.luciferase.GFP (231.luc.GFP) cells at low multiplicity of infection (MOI) to avoid
integration of multiple kinases into a single cell. G418 selection of the kinase-overexpressing
cells began at a concentration of 400 μg/mL and increased by 200 μg/mL every 3 days, up to
a total concentration of 1 mg/mL. At this point, (14 days post-infection) RNA was isolated from
some of the cells and analyzed by RT-PCR targeting a 250-bp sequence within the Neomycin
resistance (NeoR) marker, which is contained in in the kinase library vector as a selection
marker and conveys G418 resistance to eukaryotic cells. The results, seen in Figure 18,
showed a band at the expected size of 250 bp.

Figure 18. Neomycin resistance marker is present in MDA-MB-231 cells transfected with
kinase ORF pools. Following retroviral transduction with kinase pools and G418 selection, RTPCR was performed using primers specific for a 250-bp portion of the G418 resistance marker.
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The kinase pool-overexpressing 231.luc.GFP and corresponding control cells, which
expressed tandem dimer Tomato, a bright RFP [tdTomato, (207)], were used for the brain
metastasis growth screen. The cells were mixed at a 3:1 ratio (kinase pool:control), as the
kinase pool population consisted of numerous (up to 24) subpopulations of cells overexpressing
each kinases of the pool individually, and injected into 5 animals per pool via the left common
carotid artery, see Figure 19 for details. Luciferase was detected in the mice 24 hours later,
thus ensuring successful injections. It was expected that if no kinases in a given pool imbued
the 231.luc.GFP cells with a growth advantage, the mice would require euthanasia around day
60 post-injection, based on previous observations on the growth characteristics of the MDAMB-231 cell line. Additionally, as the internal control cells were labeled with tdTomato instead
of GFP, pools containing potential “hits” should lead to a much higher ratio of GFP:tdTomato
signal by fluorescence imaging.
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Figure 19. Schematic of in vivo kinome screen for drivers of brain metastatic growth.
MDA-MB-231 parental cells (231p) stably expressing luciferase, GFP, and pools of up to 24
kinases (231p.luciferase.GFP) were mixed with 231p cells expressing TdTomato and an empty
pWZL-Neo-Myr-Flag-DEST vector (231p.TdTomato). Cells were mixed at a 3:1 ratio of kinase
pool:vector and 2 x 106 cells were injected into nude mice. When animals displayed neurological
symptoms and their heads were determine to be extremely luciferase-positive by IVIS, mice
were sacrificed and brain lesions isolated using a dissecting microscope based on GFPpositivity. Portions of the lesions were subjected to direct RNA extraction, while the remainder
was dissociated and the cells cultured in vitro as passage 0. gDNA was extracted from the
recovered cells and kinase vector sequences amplified by targeted PCR. This DNA was
sequenced by MiSeq, yielding a quantitative readout of in vivo selection.
Indeed, most of the kinase pools led to dramatic phenotypes, with mouse survival
reduced from 60 days to approximately 40 days, which is more reminiscent of the brain-selected
line MDA-MB-231.Br (208) than the parental MDA-MB-231 cell line. Prior to euthanasia, the
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mice were imaged by IVIS to determine luciferase signal (Figure 20). When the mouse brains
were examined for fluorescence by dissecting microscope, it was evident that the GFP signal
was predominant; any tdTomato signal observed in brains of mice sacrificed at early time points
was of relatively minor contribution (Figure 21).

Figure 20. IVIS images of pool 9 mice 45 days post-injection. Mice from pool 9 are shown
for representative purposes. Mice are numbered 9-1 to 9-5 to reflect order in which they were
euthanized. Mice 9-1, 9-2, and 9-3, which appear emaciated and hunched in this image, were
sacrificed immediately following IVIS imaging, with 9-4 and 9-5 following 3 days later.
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Figure 21. Mouse brains are strongly positive for GFP following injection with pool 9overexpressing cells. Mouse brains were removed and examined using a SteREO
Discovery.V20 dissecting microscope (Zeiss). While some TdTomato signal was visible in the
brains of injected mice (9-2 and 9-5), the lesions were predominantly GFP-positive. Fluorescent
images shown are at 8x magnification.

After imaging brains for fluorescence, the tissue was finely minced; half was stored in
RNAlater until the time of RNA extraction and half was used in an attempt to recover the in vivoselected tumor cells. The in vivo-derived cells recovered in this way were aliquoted when they
reached 70-80% confluence and stored for later analysis (Figure 22, Table 4).
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Figure 22. Brain metastasis cells recovered in vitro are GFP-positive. Fluorescence
signals from tumor cells that were successfully recovered from in vivo lesions were assessed
by an Olympus IX70 fluorescent microscope. Nearly all of the tumor cells were GFP-positive
and TdTomato-negative. Images shown here are from mouse 9-1 (pool 9). Images were
acquired using a 10x objective and DPController software (Olympus).

Table 4. Summary of sample information for kinome screen experiments
Pool
number

Animals in group

Animals sacrificed before
day 60

Animals from which cells
successfully recovered

1

4

4

2

2

5

5

4

3

4

4

2

4

5

4

4
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5

5

5

4

6

5

5

1

7

5

5

5

8

5

5

4

9

5

5

5

10

5

0

0

11

4

4

3

12

5

0

0

13

5

5

3

14

6

6

6

15

5

5

3

16

5

0

0

17

5

4

2

To determine which kinases were responsible for the growth advantages observed in
vivo, it was necessary to employ genetic sequencing techniques. Initially, RNA isolated directly
from brains or those recovered cell lines successfully established from brain metastases was
subjected to kinase vector-specific RT-PCR and analyzed by gel electrophoresis. The results
showed that the banding patterns were indeed different in the in vivo-selected brain tissue and
recovered brain metastatic cells compared to their corresponding pre-injection controls (Figure
23).
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Figure 23. PCR analysis provides evidence of selection occurring in vivo. DNA gel
showing PCR (left) and RT-PCR (right) with kinase vector-specific primers. Banding pattern
strikingly differs between in vitro, pre-injection cells (Pool 4) and tumor cells recovered from
brain metastasis-bearing animals (4-1 through 4-4). 25ng of gDNA or 50ng of cDNA served as
PCR templates.

Following RT-PCR with Taq DNA polymerase, TOPO cloning was used to isolate
individual kinase sequences. The pooled PCR products representing each in vivo sample were
TOPO cloned, and 10 bacterial clones per each in vivo sample were grown in LB and
miniprepped. The resulting DNA was sequenced, and this approach identified 8 kinase
sequences isolated from in vivo samples from pools 1 to 5, included below in Table 5.

Table 5. Kinase sequences detected by TOPO cloning of cDNA from recovered tumor
cells from pools 1 to 5.
NCBI Gene
ID

Official
Symbol

Gene Description

RefSeq Accession
Number

1163

CKS1B

CDC28 protein kinase regulatory
subunit 1B

NM_001826

1111

CHEK1

CHK1 checkpoint homolog (S.
pombe)

NM_001274
67

7371

UCK2

uridine-cytidine kinase 2

NM_012474

3932

LCK

lymphocyte-specific protein tyrosine NM_005356
kinase

5127

PCTK1

PCTAIRE protein kinase 1, transcript NM_006201
variant 2

150274

RP3366L4.2

J-type co-chaperone HSC20

805

CALM2

calmodulin 2 (phosphorylase kinase, NM_001743
delta)

8877

SPHK1

sphingosine kinase 1

NM_172002

NM_021972

Seeking a more quantitative and comprehensive identification of all those kinase
sequences enriched in vivo, we set out to use NGS to analyze the brain metastatic cells
recovered from the mice. Because of the stable retroviral integration of the kinase ORFs into
the genome of the MDA-MB-231 prior to tumor cell injection, it was possible to analyze the
gDNA of the tumor cells for kinase enrichment. gDNA was extracted from the pre-injection and
recovered tumor cells, and quantitative PCR using kinase vector-specific primers performed on
the gDNA (Figure 23, left). This DNA was barcoded and sequenced by MiSeq (Illumina). The
raw sequence files were mapped to the human genome and the total read count of each
barcode normalized by Dr. Jun Yao, a bioinformatician in the Department of Molecular and
Cellular Oncology at UTMDACC. The reads of each kinase sequence in every brain metastasisderived sample were compared relative to their expression in the pre-injection kinaseoverexpressing cells (Figure 24), and the kinases were ranked according to average
enrichment in vivo. Focusing only on those kinases enriched (relative expression >1) in multiple
animals resulted in a list of 31 sequences (Table 6).
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Figure 24. Coverage plots reveal relative sequence enrichment following in vivo
selection. Comparison of kinase sequence read counts prior to and following in vivo selection
demonstrates appreciable loss of most sequences in vivo. The lone exception, indicated with a
blue arrow, is MAPK12, which had its read count rise from just over 2 million to 11 million.
Coverage plots were generated with MiSeq Reporter.
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Table 6. Kinase sequences enriched in vivo as determined by NGS.
NCBI
Gene ID

Official
Symbol

Gene Description

RefSeq Accession
Number

79934

ADCK4

aarF domain containing kinase 4

NM_024876

269

AMHR2

anti-Mullerian hormone receptor, type II

NM_020547

695

BTK

Bruton agammaglobulinemia tyrosine kinase

NM_000061

805

CALM2

calmodulin 2 (phosphorylase kinase, delta)

NM_001743

808

CALM3

calmodulin 3 (phosphorylase kinase, delta)

NM_005184

814

CAMK4

calcium/calmodulin dependent protein kinase NM_001744
IV

1020

CDK5

cyclin-dependent kinase 5

8851

CDK5R1

cyclin-dependent kinase 5, regulatory subunit NM_003885
1 (p35)

1198

CLK3

CDC-like kinase 3

NM_001292

26007

DAK

dihydroxyacetone kinase 2 homolog

NM_015533

2444

FRK

fyn-related kinase

NM_002031

3099

HK2

hexokinase 2

NM_000189

3985

LIMK2

LIM domain kinase 2

NM_005569

5609

MAP2K7

mitogen-activated protein kinase kinase 7

NM_145185

6300

MAPK12

mitogen-activated protein kinase 12

NM_002969

5598

MAPK7

mitogen-activated protein kinase 7, transcript NM_002749
variant 2

57787

MARK4

MAP/microtubule affinity-regulating kinase 4

NM_031417

10298

PAK4

p21(CDKN1A)-activated kinase 4

NM_001014831

5106

PCK2

phosphoenolpyruvate
(mitochondrial)

5127

PCTK1

PCTAIRE protein kinase 1, transcript variant 2 NM_006201

5211

PFKL

phosphofructokinase, liver

NM_001002021

5213

PFKM

phosphofructokinase, muscle

NM_000289

carboxykinase

NM_004935

2 NM_004563
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10654

PMVK

phosphomevalonate kinase

NM_006556

5567

PRKACB

protein kinase, cAMP-dependent, catalytic, NM_002731
beta

5568

PRKACG

protein kinase, cAMP-dependent, catalytic, NM_002732
gamma

5580

PRKCD

protein kinase C, delta

NM_006254

5584

PRKCI

protein kinase C, iota

NM_002740

6794

STK11

serine/threonine kinase 11

NM_000455

83983

TSSK6

testis-specific serine kinase 6

NM_032037

7371

UCK2

uridine-cytidine kinase 2

NM_012474

51530

ZC3HC1

zinc finger, C3HC-type containing 1

NM_016478

Generating such an extensive list of potential novel drivers of brain metastatic growth
was promising; however, as the kinome screen was performed in a pooled format, the possibility
existed that some of the would-be hits were mere artifacts of the screening process, passenger
genes being buoyed by their neighbors. Therefore, all the potential hits require functional
validation before being truly implicated in brain metastasis. In order to do so, the ORFs
representing the potential “hit” kinases were individually used to generate stable MDA-MB-231
transfectants. As it would have been time- and cost-prohibitive to interrogate all 31 ORFs in
mice, another filter for hit prioritization proved necessary. Tumor cell growth in hard agar (0.9%)
has been previously established to be indicative of brain metastasis-initiating potential (209), a
secondary functional screen was performed on single ORF-overexpressing cell lines. The
assay indeed demonstrated differences among the potential hits in their ability to form colonies
in hard agar, further informing “hit” ranking (Figure 25, Table 7).
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Figure 25. In vitro hard agar growth assay of single kinase-overexpressing MDA-MB-231
cells shows that overexpression of most kinases enhances colony formation. Colonies
>75 μm following 60 days of culture were counted. One-way ANOVA showed significant
difference between groups, F(22,46)=15.56, p<0.0001. Fisher’s LSD multiple comparisons test
showed that the top 10 cell lines had a statistically significant colony-forming advantage over
the vector group, indicated with * on the graph. Experiments were performed in triplicate. Error
bars indicate SEM of colony number per well.

Because the kinome screen was based on the principle of generating artificial
heterogeneity prior to testing for in vivo selection, it was necessary to demonstrate that the
newly identified hits are actually expressed in human brain metastases and did not exist
exclusively in the artificial setting of this screen. Through a collaboration with the a group from
the University of Queensland (Australia), we examined the expression of all potential hits by
RNA-seq of a collection of 32 human brain metastasis specimens, including 8 cases of breast
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cancer (205). Analysis showed again showed a wide range of expression, with CALM2 and
HK2 expressed in the top 5% of all expressed genes (Figure 26, Table 7).

Figure 26. Expression of putative kinase hits in human brain metastasis according to
RNA-seq. Genes are ordered according to average expression (normalized to transcripts per
million reads, nCPM) in all samples. Solid gray line distinguishes those genes expressed as
upper outliers, calculated as [Q3+(1.5 x IQR)]. Dashed gray line indicates those genes
considered as “expressed,” as their transcript expression level was greater than 1 transcript per
million. Error bars indicate SEM of nCPM.

The expression data in brain metastasis was then combined with the hard agar colonyforming ability to rank the potential hit kinases in order of likelihood of their contribution to
accelerated brain metastatic growth. The top-ranking potential hit thus identified was PCTK1
(Table 7).
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Table 7. PCTK1 is the top candidate kinase based on hard agar colony-forming ability
and expression in human breast cancer brain metastases.
Gene

Hard agar colony
formation rank

Human brain metastasis
expression rank

Rank-sum

PCTK1

5

5

10

STK11

1

13

14

CALM3

14

3

17

CLK3

3

14

17

HK2

15

2

17

PRKACB

11

6

17

LIMK2

10

8

18

PRKCI

11

7

18

PFKM

8

11

19

CALM2

19

1

20

DAK

2

19

21

PFKL

17

4

21

FRK

11

10

21

UCK2

16

9

25

PMVK

11

15

26

CDK5R1

4

23

27

MAP2K7

11

16

27

PRKCD

11

18

29

MAPK7

9

21

30

MARK4

20

12

32

ADCK4

13

20

33

ZC3HCI

12

22

34

AMHR2

7

28

35

PRKACG

6

29

35
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CAMK4

11

26

37

PCK2

21

17

38

TSSK6

11

27

38

BTK

11

30

41

PAK4

11

31

42

MAPK12

18

25

43

CDK5

22

24

46
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Chapter 4: Investigation and validation of PCTK1 as a driver of brain metastatic growth
PCTK1, also known as cyclin-dependent kinase 16 (CDK16), is a serine/threonine
kinase originally named PCTAIRE-1 after its discovery in 1992 (210). It exists in 3 isoforms,
with isoform 1 encoding a protein of 55.7 kilodaltons (kDa) and isoforms 2 (63.4 kDa) and 3
(56.4 kDa) possessing extended N-terminal domains. It is classified as an atypical cyclindependent kinase (cdc2/CDC28-related protein kinase gene family) family member, as its
cyclin-binding domain contains a serine to cysteine substitution (i.e., PCTAIRE instead of
PSTAIRE) (210). This non-traditional cyclin-binding domain leads to binding of cyclin Y (CCNY)
(211). A PCTK1 knockout mouse model revealed that PCTK1 is indispensable for
spermatogenesis; homozygous knockout male mice are infertile, while females produce viable
offspring (211). No other phenotypes of the knockout model were noted (211). However,
commensurate with its mRNA expression in the brain, PCTK1 has also been shown to regulate
neuronal differentiation and outgrowth (212). Intriguingly, this kinase has also been identified
as a substrate of CDK5, another kinase identified in the previous in vivo kinome screen (213).
Phosphorylation of PCTK1 by activated CDK5 is required for its activity in dendrite development
(214).
In spite of the gains made in better understanding the physiological roles of PCTK1, a
great deal of its characterization remains elusive. First and foremost, as a kinase, PCTK1 is
thought to primarily function through phosphorylation of downstream targets. Indeed, it
possesses an activation loop and has been shown to phosphorylate N-ethylmaleimide-sensitive
fusion protein (NSF) (215), KAP0 (216), and cyclin Y (217). However, elegantly designed
studies attempting to characterize a consensus substrate motif for PCTK1 have failed to agree
with each other (216, 218), although they did both conclude that the PCTK1 substrate motif
does not coincide with that of typical CDK family motifs. In addition to the lack of clarity of
PCTK1’s targets, its upstream regulators remain a topic of debate, as the role of cyclin Y as the
sole activator of PCTK1 has been questioned, with both cyclin Y-like 1 (CCNYL1) (219) and
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CDK5 (212) suggested as alternative regulators. Therefore, unlike classic proliferation-related
cyclins, it may be that the activity of PCTK1 is totally independent of cyclin binding.
PCTK1 has only recently been implicated in cancer, and its biological roles in this
disease setting remain largely unresolved. It has been demonstrated in vitro that PCTK1
knockdown sensitizes prostate and breast cancer cells to the TNF-related apoptosis-inducing
ligand (TRAIL) extrinsic cell death pathway (220). Additionally, PCTK1 has been shown in
prostate cancer cells to phosphorylate the tumor suppressor p27 (also known as Kip1, cyclindependent kinase inhibitor 1B), resulting in its degradation and cell cycle progression (221). In
an in vitro screen, it was shown that siRNA-mediated knockdown of PCTK1 slowed the growth
of a MYC-amplified medulloblastoma cell line, suggesting PCTK1’s involvement in the
mammalian target of rapamycin (mTOR) pathway. Lastly, PCTK1 has been shown to be
overexpressed at the mRNA and protein levels in serous epithelial ovarian carcinoma (EOC)
tissues compared to matched normal tissues, although the authors suggest that this is a
negative feedback mechanism to promote the differentiation of tumor cells and inhibit
proliferation. Notably, the involvement of PCTK1 in metastasis has thus far been unexplored.
PCTK1 was the top candidate kinase based upon its expression in clinical brain
metastasis as well its ability to enhance colony formation in hard agar, but because the kinome
screen was performed in a pooled format, it was necessary to functionally validate PCTK1 in a
single kinase-overexpression context. Therefore, the PCTK1-overexpressing MDA-MB231.luc.GFP (231.PCTK1) and its corresponding control line (231.vector) generated for the
hard agar screening experiments were validated for PCTK1 overexpression at the mRNA and
protein levels (Figure 27) and were injected into the carotid artery of mice (100,000 cells per
mouse). The cell number was halved in this experiment compared to the kinome screen in order
to provide a larger window of observation. Following intracarotid injection, the mice were
monitored weekly by IVIS luciferase imaging and sacrificed when they reached morbidity.
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Figure 27. PCTK1 is overexpressed at RNA and protein level in 231.PCTK1 cells. Left:
qRT-PCR with TaqMan primers shows that PCTK1 mRNA expression is enhanced more than
sixfold compared to controls. qRT-PCR of 18S mRNA was used for normalization. The p-value
was <0.0001 according to unpaired t-test. Right: Western blot for PCTK1 protein expression.
β-actin was used as a loading control.

PCTK1 overexpression led to enhanced brain metastatic growth relative to the vector
control cells to the extent that luciferase images of the mouse brains began to become saturated
by day 32 post-injection (Figure 28). Additionally, PCTK1-overexpressing cells significantly
reduced mouse survival relative to the control group, demonstrating that PCTK1 indeed can
accelerate brain metastasis growth even outside the pooled format of the kinome screen
(Figure 29). The brain metastases formed by 231.PCTK1 were invasive from the leptomeninges
into the parenchyma, and formed large ventricular masses, while 231.vector mostly formed
smaller tumors in the ventricles (Figure 30).
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Figure 28. PCTK1 overexpression enhances brain metastasis growth in vivo. IVIS imaging
was performed using an IVIS-200 (Xenogen) to assess the growth of brain metastases in vivo.
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MDA-MB-231.luciferase cells expressing vector (231.vector) or PCTK1 (231.PCTK1) were
injected into the carotid artery of nude mice to form experimental brain metastasis (each group:
n = 10). Metastatic growth in the brain was measured beginning 1 day post-injection by
luciferase activity. Top: IVIS images from 5 representative mice per group are shown. The scale
bar to the right of the images indicates signal intensity, a surrogate marker of brain metastasis
burden. The signal from mice injected with 231.PCTK1 started to become saturated by day 32
post-injection. Bottom: quantification of IVIS luciferase signal. The y-axis shows the amount of
luminescence captured from a defined region of interest (ROI), which was an oval-shaped
region of standardized size around each animal’s head. T-tests were performed at each time
point and the Holm-Sidak method was used to correct for multiple comparisons.

Figure 29. PCTK1 overexpression in MDA-MB-231 significantly shortens survival in
experimental brain metastasis model. Mice injected intracarotidly with 231.PCTK1 or
corresponding vector cells were compared for their brain metastasis-specific survival. PCTK1
overexpression shortened survival from a median time of 128 days to 60 days. Survival curves
were significantly different (p=0.0004) according to Mantel-Cox log-rank test.
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Figure 30. PCTK1 overexpression enhances brain metastasis growth in ventricles and
invasion into the parenchyma. (A) and (B): Hematoxylin and eosin (H&E) staining of
231.vector brain metastases. 231.vector cells formed lesions in the ventricles (A) and small
lesions in the parenchyma (B). (C) and (D) H&E staining of 231.PCTK1 brain metastases. (C)
shows tumor cells growing throughout the parenchyma, while (D) shows 231.PCTK1 cells filling
the ventricle. All images acquired at 10x magnification; scale bars represent 200 µm.
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After the observation of PCTK1’s enhancement of brain metastasis, and given the limited
functional knowledge about PCTK1, a natural question was whether the PCTK1-driven tumor
growth was metastasis-specific or a shared feature of primary tumors and metastases.
Therefore, luciferase-labeled 231.vector or 231.PCTK1 were injected into the mammary glands
of nude mice to form mammary fat pad tumors (each group: n = 12 [6 mice with bilateral
tumors]). PCTK1 overexpression did not lead to enhanced primary tumor growth in this model,
suggesting that its pro-tumoral functions are metastasis-specific (Figure 31).
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Fig 31. PCTK1 overexpression does not enhance primary mammary tumor growth.
231.PCTK1 and 231.vector were injected into the #3 mammary glands of nude mice. Injection
efficiency was measured on day 1 by IVIS. Once tumors became palpable, they were regularly
measured by calipers. Tumor volume estimates, calculated by the formula (L x W 2)/2 and
normalized to IVIS signal on day 1, are shown in A. Tumor mass as determined at the
experimental endpoint is shown in B. Unpaired t-tests, using the Holm-Sidak method to correct
for multiple comparisons, revealed no significant growth differences.
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To characterize the cellular mechanism by which PCTK1 enhances brain metastatic
growth of MDA-MB-231 cells, basic cellular phenotypic characteristics, including proliferation,
invasion, and migration were assessed in vitro under normal culture conditions, i.e., DMEM/F12
media supplemented with 10% FBS. The results, as shown below in Figure 32, indicated that
PCTK1’s dramatic pro-metastasis phenotype was not recapitulated in vitro.

Figure 32. PCTK1 overexpression does not promote proliferation, migration, or invasion
in vitro. (A) MTT assays demonstrated a statistically significant difference at the 2 day time
point, but no dramatic biological difference was observed. (B) Transwell migration assay of
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231.vector and 231.PCTK1 at 18 hours showed no significant difference. (C) Invasion through
Matrigel at 24 hours was inhibited by PCTK1 overexpression. Unpaired t-tests were used to
compare groups in each experiment and the results are indicated as * on graphs. In A,
correction for multiple comparisons was performed.

Based on the characterization of PCTK1 as a non-canonical cyclin-dependent kinase,
the fact that it provided no major growth advantage in vitro was unsurprising. At the same time,
the strikingly rapid growth of PCTK1-overexpressing brain metastatic cells in vivo demanded
explanation. As mentioned in Section 1.3.2, the brain represents a vastly distinct habitat
compared to the primary tumor site, especially with regards to resource availability. Therefore,
to examine whether growth advantage conferred by PCTK1 in brain metastasis may be related
to the unique metabolic microenvironment of the brain, correlations of PCTK1 gene expression
with the expression of members of the glutamine metabolism pathway were analyzed (Figure
33, A - E). Strikingly, in primary breast cancer as well as glioblastoma, PCTK1 showed strong
relationships with expression of glutamine metabolizing genes, including asparagine
synthetase (ASNS). These relationships were even stronger in low-grade glioma, where they
extended to both forms of the classical glutamine catabolism gene glutaminase, glutaminase 1
and 2 (GLS and GLS2).
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Figure 33. PCTK1 shows strong correlations with glutamine metabolism genes in TCGA
data. The gene expression values of PCTK1 (CDK16) and members of the glutamine metabolic
process (Gene Ontology: 0006541) family were compared within TCGA datasets of ER-positive
breast cancer (A), HER2-positive breast cancer (B), TNBC (C), glioblastoma (GBM) (D), and
low-grade glioma (LGG) (E). Pairwise Pearson correlation coefficient values between genes
were generated and reordered using a clustering algorithm based on the similarity between
genes. Genes with highly positive correlative values appear in red, those with highly negative
values in blue, and those lacking correlation in white. PCTK1 is highlighted in each graph. Data
matrices were generated by Dr. Patrick Zhang.
.
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In consideration of this correlative relationship with glutamine metabolism, the effect of PCTK1
was functionally assayed in vitro in low nutrient conditions. For this purpose, Basal Medium
Eagle (BME), which was developed by Harry Eagle in the 1950s for growing HeLa cells (222,
223), was selected. Basal Medium Eagle contains approximately one-third the glucose and
one-fourth the amino acid content of DMEM/F12, which is more widely used in cell culture
because its nutrient surplus supports a higher growth rate. Importantly, when 231.PCTK1 and
231.vector were previously compared for their proliferative abilities in vitro, DMEM/F12 media
was used. When the assay was repeated using BME supplemented with 500 μM glutamine
(representative of physiological level in the brain), PCTK1 overexpression imbued the cells with
a striking growth advantage (Figure 34). This result provided an indication that PCTK1 may
allow cells to better metabolize glutamine when faced with low-nutrient conditions, such as that
of the brain.
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Figure 34. PCTK1-overexpressing cells have a survival advantage in low-nutrient
conditions when glutamine is available 231.PCTK1 cells or 231.vector cells were plated with
or without 500 μM of glutamine. After one week, cell growth was assessed by an Olympus IX70
microscope. Representative images at 10x magnification are shown.

Because the exchange of glutamine and glutamate occurs in the brain in a cyclical
fashion, it was unclear whether the PCTK1-overexpressing cells were using the glutamine from
the media directly, or perhaps were driven to proliferation by activation of glutamate receptors.
Therefore, the relative abilities of PCTK1-overexpressing and associated vector control MDAMB-231 cells to proliferate using similar concentrations of either glutamate or glutamine were
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assayed in low-nutrient BME. While vector-expressing cells were unable to grow with either
glutamate or glutamine supplementation, the PCTK1-overexpressing cells demonstrated a
strong growth advantage evident at glutamine concentrations ranging from 400 μM to 2mM
(Figure 35A). However, even the PCTK1-overexpressing cells were unable to grow with
comparable levels of glutamate supplementation (Figure 35B). These results suggested that
PCTK1-overexpressing tumor cells indeed behave similarly to neurons under limiting nutrient
conditions, with an ability to use glutamine but not glutamate for survival and/or proliferation.
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Figure 35. PCTK1-overexpressing cells have proliferative advantage in limited-nutrient
media supplemented with glutamine, but not glutamate. MDA-MB-231 cells with or without
PCTK1 expression were cultured in BME with the given quantities of glutamine (A) or glutamate
(B) for 4 days. MTT assays were performed, and the results are shown in terms of MTT signal
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at 570 nm minus the background at 650 nm (OD 570-650). T-tests were performed at each
concentration, with the Holm-Sidak method used to correct for multiple comparisons.

While the previous results indicated that 231.PCTK1 cells were using glutamine in order
to maintain their survival and proliferation in conditions of limited nutrients, it remained unknown
whether the cells were indeed taking up more glutamine and either using it for energy or
incorporation into the biomass of new cells, or simply processing the glutamine a byproduct of
a homeostatic glutamine-glutamate cycle. In order to directly test these possibilities, the media
of PCTK1-overexpressing and vector MDA-MB-231 cells was analyzed by mass spectrometry.
In order to calculate the relative rates of substrate utilization, media was collected at the
specified timepoints (0, 1.5, 3, and 6 hours) and the relative peaks of glutamine and glutamate
compared. Because of the sensitivity of the experiment to environmental conditions, wells
included as replicates were randomly selected from different regions of the cell culture plates
(See schematic, Figure 36).
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Figure 36. Schematic of MS experiment to determine relative glutamine and glutamate
utilization rates in PCTK1-overexpressing cells. (A) Cells were cultured in 12-well plates in
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300 μL BME with exactly 500 μM glutamine at the start of the assay. Media was collected from
wells sampled from around the plate at time points indicated within circles (times are in hours)
and centrifuged at 2000 x g for 5 minutes to remove cellular debris. The media from earlier time
points was stored at -80°C until completion of the assay, at which time all samples were
analyzed for glutamine and glutamate content by YSI Bioanalyzer. (B) Results indicated that
the rate of glutamine intake rose in 231.PCTK1 cells, while at the same time the glutamate
output rate actually decreased.
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Figure 37. PCTK1 overexpression significantly enhances glutamine metabolism. (A) Left,
glutamine depletion rates in the media of 231.vector and 231.PCTK1 were compared by MS.
There was a trend towards increasing glutamine consumption with PCTK1 overexpression.
Right, similar comparisons were made for glutamate release into the media of cultured cells.
There was a significant decrease in glutamate release from PCTK1-overexpressing cells. (B)
The rate of glutamate production was normalized to the rate of glutamine consumption. PCTK1
overexpression led to a deficit in glutamate production per glutamine consumed of nearly 50%.
Unpaired t-tests were used to compare groups in each experiment and the results are indicated
as * on graphs.

These results demonstrated several important points. First, the rates of glutamine
consumption from and glutamate release into the media remained in the linear range over the
time frame assayed, for simplicity the 0 hour and 6 hour time points were compared. Compared
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to 231.vector cells, the PCTK1-overexpressing cells increased their uptake of glutamine from
the media by 35% (Figure 37A, left). At the same time, there was a reduction in glutamate
release from the PCTK1-overexpressing cells, with the relative rate falling by more than 25%
(Figure 37A, right). Together, these rates meant that for every 1 unit of glutamine going into the
cells, PCTK1-expressing cells were producing 48% less glutamate (Figure 37B). This deficit
between expected glutamate release and actual glutamate release implies that the glutamine
is staying in the cell for either energy or biomass generation.
Finally, as all of the prior experiments had been based on a gain-of-function system,
loss-of-function studies were performed in order to test whether PCTK1 was necessary for brain
metastasis in vivo. To that end, PCTK1 stable knockdown cell lines were generated from the
HCC1954Br cell line (1954Br), a highly aggressive HER2-overexpressing breast cancer cell
line that also possesses a high endogenous level of PCTK1. PCTK1 knockdown efficiency at
the mRNA and protein levels for the 2 best clones are shown below in Figure 38. HCC1954Br
shControl and HCC1954Br shPCTK1-3 were then injected into the carotid artery of nude mice.
Following intracarotid injection, the mice were monitored for development of brain metastasis
symptoms

and

sacrificed

when

they

reached

morbidity.
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Figure 38. PCTK1 is efficiently knocked down in the HCC1954Br cell line. Left: qRT-PCR
with TaqMan primers shows that PCTK1 mRNA expression is decreased 90% in both
knockdown lines compared to control line. qRT-PCR of 18S mRNA was used for normalization.
The p-value was <0.0001 according to one-way ANOVA followed by Dunnett’s multiple
comparisons test. Right: Western blot for PCTK1 protein expression showing efficient
knockdown with both shRNA clones. β-actin was used as a loading control.
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Figure 39. PCTK1 knockdown in HCC1954Br significantly extends survival of brain
metastasis-bearing mice. Mice injected intracarotidly with 1954Br shControl or shPCTK1
were compared for their brain metastasis-specific survival. PCTK1 knockdown lengthened
survival from a median time of 57.5 days to 91 days. Survival curves were significantly different
(p=0.046) according to Mantel-Cox log-rank test.
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Figure 40. PCTK1 knockdown does not affect morphology of brain metastasis in
HCC1954Br model. Representative H&E staining of brain metastasis formed by ICA injection
of (A) HCC1954Br shControl cells on day 49 post-injection or (B) HCC1954Br shPCTK1-3 cells
on day 91 post-injection. No major morphological differences were apparent between groups,
with both exhibiting parenchymal growth, large volume, and abundant vasculature. All images
acquired at 10x magnification; scale bars represent 200 µm.
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Knockdown of PCTK1 in the 1954Br cell line significantly enhanced mouse survival
relative to controls in an experimental brain metastasis model, with median survival times rising
from 57.5 days in the control group to 91 days in the knockdown group (Figure 39). However,
as most mice injected with PCTK1 knockdown clones eventually succumbed to brain
metastases with morphology resembling the control tumors (Figure 40), knockdown of PCTK1
unsurprisingly did not seem to be a curative approach. To investigate whether the expression
of PCTK1 recovered in vivo, either through adaptation or selection of clones with inefficient
knockdown, the protein level of PCTK1 was assessed by IHC. Indeed, IHC analysis showed
that PCTK1 expression can recover in vivo (Figure 41), indicating either that the incomplete
efficiency of shRNA in eliminating protein expression or the selection of especially poor
knockdown clones in vivo.
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Figure 41. PCTK1 protein expression can recover in vivo in HCC1954Br brain
metastasis with PCTK1 shRNA knockdown. Representative PCTK1 IHC staining of brain
metastasis formed by ICA injection of (A & B) HCC1954Br shControl cells or (C & D)
HCC1954Br shPCTK1-3 cells. Both the control and PCTK1 knockdown brain lesions show
heterogeneous PCTK1 expression, with areas of almost uniform positivity and negativity both
apparent. All images acquired at 20x magnification; scale bars represent 100 µm.
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Chapter 5: Discussion, Conclusions, and Future Directions
Discussion
Breast cancer is one of the most common and deadly cancers among women in the
United States, as almost 250,000 new cases will be diagnosed in 2016, and an expected 40,500
deaths due to breast cancer. In the past 30 years, the increase in screening and targeted
therapies for breast cancer has seen the death rate fall by almost one-third from its peak in
1989. However, this improvement is almost entirely due to effects in detecting early-stage
disease earlier; once cancer has metastasized, the prognosis remains bleak, as patients
diagnosed with stage IV disease (distant metastasis) have only a 22% 5-year survival.
The metastasis of cancer to secondary sites is not a random process, as cancers from
certain organ sites have their own preferential sites for metastasis. The ‘seed and soil’ principle
holds that successful metastasis only occurs when the right cancer cell seed interacts with the
appropriate supportive secondary organ soil. First espoused by English surgeon Stephen Paget
in 1889 and validated by Isaiah Fidler in the 20th century, the seed and soil theory has stood
the test of time. For breast cancer seeds, the common metastatic soils are bone, liver, lungs,
and brain. While any metastatic breast cancer diagnosis is generally fatal, brain metastasis
carries a brutal prognosis, with median survival of less than one year.
The especially poor prognosis for brain metastasis is not limited to the context of breast
cancer. Other cancers that frequently metastasize to the brain include lung, breast, melanoma,
and colorectal; once they are in the brain, all are incurable. While one explanation is the fact
that brain metastases usually develop in heavily pre-treated patients, so do metastases to other
organ sites that can demonstrate responses to therapy; brain metastases’ therapeutic
resistance is likely due to the unique biology of the brain. In either case, the clinical options for
brain metastasis are only palliative; this and the fact that it is not even fully resolved as to why
secondary cancers of the brain do not respond to therapy represent true failures by the clinical
and biomedical research communities.
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In cancer settings other than brain metastasis, molecular targeted therapies against
cancer drivers, frequently kinases, have demonstrated widespread clinical efficacy.
Additionally, as kinases occupy the key nodes of cancer cell signaling pathways, they are
involved in many of the cellular functions and dysfunctions that represent the hallmarks of
cancer. In vitro, kinase overexpression screens have identified previously unknown oncogenes.
Finally, while genomic and transcriptomic studies comparing brain metastases to either primary
cancers or non-brain metastasis have identified a number of brain-specific genes that play roles
in brain metastasis, these studies are restricted to those genes whose mRNA expression
remains significantly altered following the formation of brain metastasis. As the process of
metastasis involves many diverse and demanding steps, genes that provide an advantage at
one step may be antagonistically pleiotropic, causing their loss of expression at later stages.
Therefore, we set out to identify novel kinase drivers of brain metastasis through a
functional genomic screen in vivo, hypothesizing that kinases previously unknown to play roles
in brain metastasis may actually imbue cancer cells with growth advantages in the brain. By
using the intracarotid injection method of inducing experimental brain metastasis, the cells are
delivered into the capillary bed of the brain, allowing for the observation of brain metastasis,
which is incredibly rare in other models. This also has the effect of focusing the interrogation of
the metastatic cascade to the final few steps: extravasation, colonization, and growth at the
secondary site. Because the dissemination of cancer cells throughout the body usually occurs
early, understanding these steps is key to the future of therapy for metastasis. The MDA-MB231 parental cell line was selected as the cancer cell background for the screen, because as
the line is able to induce brain metastasis with high efficiency but relatively long latency, it offers
a window for observing enhanced brain metastasis. One noteworthy drawback of this approach
is that the use of cross-species xenografts as models of cancer and metastasis involves the
growth of human cells in immunocompromised mouse hosts. In this study, nude mice were
used as the hosts for metastasis experiments, as the “nude” mutation in FOXN1 that causes
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their hairlessness also leads to the absence of a thymus and deficient T cell development,
thereby allowing the growth of foreign cells that would otherwise be rejected by
immunocompetent animals (224). While the use of immunocompromised mice enables the
interrogation of cancer cell growth dynamics in organ-specific nutrient environments much
closer to approximating human disease than does in vitro cell culture, the artificial nature of
such a system should not be understated. As cancer immunotherapy continues to lead to
dramatic clinical results in cancer therapy, the immune system is obviously a key regulator in
protecting against cancer and metastasis outgrowth and colonization, and the use of
immunocompromised animal models downplays this factor. Studies on the importance of the
immune system in curtailing brain colonization and growth by metastatic tumor cells could make
use of mouse cancer cell lines such as 4T1 in a syngeneic mouse background of BALB/c,
although the use of non-human cancer cell lines also raises questions of real disease relevance.
As statistician George Box said, “all models are wrong; some are useful.” With this in mind,
here I chose to focus on an experimental model system with certain limitations (experimental
metastasis model in immunocompromised mice), in hopes of identifying some novel truths that
could be validated in other systems later. While a pure brain metastasis gain-of-function screen
in a spontaneous mammary fat pad tumor model or non-brain tropic cell line using a syngeneic
immunocompetent mouse strain would have been much less likely to generate successful
phenotypes, and was not pursued here, this approach could be taken by audacious researchers
in the future.
The screen resulted in clear demonstration that kinase overexpression enhanced brain
metastasis growth, as 14 of the 17 pools decreased mouse survival shorter than the 60 days
seen in the parental cell line. Following this positive in vivo data, though, recovery of the identity
of the kinases involved was non-trivial. During the screen, as the mice were euthanized, their
brains were harvested; half of the metastases-bearing tissue (as estimated by GFP signal under
dissecting microscope) was used for direct RNA extraction and half was dissociated and cells
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were recovered from the dissociated tissue in vitro. The RNA from the brain metastasis lesions
was isolated and used to produce cDNA, which was then subjected to RT-PCR with vectorspecific primers. The resulting PCR products were then TOPO cloned and subjected to
sequencing
While this methodology did yield some potentially interesting data, it was clear that there
were limitations. First, it did not provide a quantitative measure of the kinases being detected.
Simple identification of a kinase sequence from in vivo tissue did not necessarily indicate that
a given kinase was enriched in vivo, merely that it was not completely lost from the population.
More importantly, while 5 sequences were identified from pool 2, only 1 was recovered from
pool 1 and 2 from pool 3, with none coming from pool 4 or 5 in spite of their increased brain
metastatic growth and the fact that multiple bands were visible in gels analyzing their RT-PCR
products. This was partially due to the fact that the kinase library contained 353 ORFs, but
came with 409 wells of bacterial glycerol stock. The extra 56 wells, which were distributed
throughout the plates of the library, contained the kinase ORF vector plasmid loaded with a
“filler” DNA sequence, in many cases a segment of TGFBR2. Since these filler sequences were
very short, they preferentially amplified during the PCR process and overwhelmed the true ORF
sequences during the TOPO cloning process, thereby obfuscating kinase identity.
When it became clear that the TOPO cloning method was not optimal for identifying the
kinases positively selected in vivo, the method for kinase identification was modified, instead
using NGS of genetic materials isolated from recovered tumor cells compared to the preinjection cells. Prior to performing NGS, a comparison was made between the detection
capabilities of kinase library gDNA by PCR and mRNA by RT-PCR; gDNA allowed for
amplification of more sequences and was thus chosen for further NGS analysis. The MiSeq
NGS method allowed for the quantitative measurement of kinase enrichment in vivo, and was
only limited by the fact that successful cell recovery was only achieved for 48/66 in vivo
samples. As the kinase library was expressed in a retroviral vector and stably selected prior to
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injection, it was possible to query the genomic DNA for kinase ORF presence without
dependence on a cDNA synthesis step. This NGS analysis revealed 31 kinases that were
enriched in multiple animals in vivo, many of which were previously unlinked to brain
metastasis. Of note, 2 of the ORFs (CALM2 and PCTK1) identified by the TOPO cloning method
appeared in the list of kinases enriched in vivo. However, the other 6 ORFs identified by that
method were not enriched, demonstrating the superiority of the NGS method in determining
quantitative measures of enrichment.
The overexpression of kinases in a pooled format offered the ability to survey a wider
range of kinase species simultaneously. In a small pilot study in a second cell line, we attempted
the screen with kinase pools of doubled size, representing approximately 40 kinases per pool.
These pools appeared to be too large, as there was no minimal consistency mouse-to-mouse
in terms of which kinases were enriched. However, the recovery and sequencing of this pilot
study was only performed using the TOPO cloning/Sanger sequencing method. By using the
MiSeq system for NGS, performing a similar screen with larger pool sizes should be possible.
Results could also be made more robust by including more animals, or by direct isolation and
sequencing of genomic DNA from tumor cells isolated from brain by either FACS or magnetic
bead-based isolation.
Importantly, the kinome screen as performed did reveal several kinases potentially
playing important roles in brain metastasis. Notably, HK2, which controls the first step of
glycolysis and has previously been implicated in brain metastasis (191), was one of the top hits
identified by this screen. Intriguingly, 3 other kinases enriched in vivo in multiple animals,
phosphofructokinase-liver

(PFKL),

phosphofructokinase-muscle

(PFKM),

and

phosphoenolpyruvate carboxykinase 2 (PCK2), are all associated with the utilization of glucose.
As brain metastasis has been shown to be reliant upon glucose for both the glycolytic and
pentose phosphate pathways (192), this serves as an indicator that the screen revealed
potentially relevant hits. Indeed, the study of cancer has focused almost exclusively on the use
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of glucose as an energy substrate. To wit, Otto Warburg’s observations on the preference of
cancer cells to obtain energy by anaerobic glycolysis serve as the basis for the Warburg
hypothesis (225) and 18-FDG PET imaging relies on the preferential glucose metabolism by
cancer cells as a means of differentiating them from healthy tissue (226). Intriguingly, though,
while HK2, PFKL, and PFKM all are involved in glucose metabolism via glycolysis, suggestive
of a Warburg effect, PCK2 plays the opposite role in glucose metabolism by its regulation of
gluconeogenesis. Therefore, the seeming implication of glucose metabolism in brain metastasis
might not be as simple as Warburg-driven ATP generation. While glycolysis may immediately
suggest ATP generation, it can actually serve as a substrate for biomass generation as well
(227). As both increased glycolysis (191) and increased use of other metabolic substrates (192)
have been reported in the context of brain metastasis, it will be important to identify whether
the seemingly disparate functions of glycolysis and gluconeogenesis are time- or spacedependent manifestations of metastatic response to nutrient limitations within the brain. Isotopic
tracing experiments would allow the fate of these metabolic substrates to be revealed, thereby
exposing which particular nutrients are limiting during the process of brain metastasis.
Targeting of the salvage pathways by which brain metastases obtain limited nutrients may allow
for creation of an evolutionary double bind scenario for metastasis targeting.
In addition to glucose metabolism, at least two other networks revealed themselves in
the screen. The first, calcium signaling, was indicated by the presence of CALM2, CALM3, and
CAMK4. Calcium signaling is critical for brain function. It is involved in astrocyte-neuron
communication (228), synaptic glutamate receptor activation leads to an influx of Ca2+ into
neurons, which can trigger transcriptional changes (229), and ionic calcium entry into neuronal
mitochondria stimulates oxidative phosphorylation (230) and is coupled to synaptic vesicle
release (231). In the context of cancer, calcium signaling has been shown to be activated in
prostate cancer following stimulation with bone ECM (232); calcium may also stimulate cell
migration (233). Interestingly, in the context of brain metastasis, transport of calcium from
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cancer cells to astrocytes has been shown to be chemoprotective to cancer cells (234). Lastly,
brain metastatic breast cancer cells have been shown to express GABAergic neuronal features
(235). It is plausible that they could also express glutaminergic neuronal receptors, thus
enabling enhanced calcium influx and calcium-mediated signaling. Though not yet validated,
the fact that several calcium signaling proteins were enriched in brain metastasis in vivo
suggests an important role for calcium signaling in brain metastasis.
Another interesting pathway revealed by the screen is the CDK5/CDK5R1/PCTK1 axis.
CDK5 and PCTK1 are both non-canonical CDKs, and CDK5R1 is a specific regulator of CDK5.
The three proteins are expressed in the brain and have been shown to interact in vitro and in
vivo (213); phosphorylation of PCTK1 by the CDK5/CDK5R1 complex at S95 enhances its
activity. In a screen of over 350 kinases that yielded 31 hits, the odds of three members of the
same complex being enriched accidentally are small.
However, in regards to which kinase ought to have been pursued further, the screen
results alone were not sufficiently informative. For example, which putative hit would have been
better to investigate, the one that is enriched 10-fold in two animals, or the one enriched 1.5fold in all mice of a group? While a larger sample size per group may have allowed for purely
quantitative measurements, including differential weighting of positive and negative selection,
this analysis was simple: if the average expression of a kinase in brain metastases of a group
was greater than the input cells, and if at least two animals in the group had expression >1
relative to input cells, the kinase was deemed a hit. Therefore, to further functionally rank the
putative hits, a secondary screen was performed assaying single kinase-overexpressing MDAMB-231 cells for growth in hard agar (209). This assay simultaneously measures both the
tumor-initiating capacity and invasive phenotype, both characteristics important for brain
metastasis growth. Most kinases were able to enhance the hard agar colony formation relative
to vector cells, some more than 100-fold, thus further prioritizing the hits.
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In spite of the notable relationships existing within the putative hit kinases and their
enhanced hard agar colony-forming ability, the kinome screen was built upon the principle of
functional artificial heterogeneity: kinases were overexpressed in a cell line and queried for their
potential to enhance brain metastasis growth without regard for whether or not they are actually
expressed in brain metastasis. Therefore, prior to fully committing to a certain path, it was
necessary to confirm that the putative hits were actually expressed in brain metastasis and not
mere artifacts of this artificial heterogeneity approach. While NGS data on human brain
metastasis is incredibly rare, an Australian group recently published NGS data on 36 human
brain metastases, including 10 cases from breast cancer (205). Through a collaboration, the
kinase hits identified in the screen were analyzed in their data. The results showed that all but
2 of the kinome screen hits are expressed in human brain metastases, and are therefore not
simply screen artifacts. Provocatively, the top 7 genes, whose expression exceeded the upper
outlier threshold of [Q3+1.5 x IQR], included CALM2, CALM3, HK2, PFKL, and PCTK1. Based
on the rank-sum score of the kinase hits in hard agar colony formation and human brain
metastasis, PCTK1 was selected for validation.
PCTK1 overexpression in the MDA-MB-231 cell line indeed enhanced brain metastasis
growth and decreased mouse survival in the experimental brain metastasis setting. The
resulting metastases included large lesions in the ventricles and leptomeninges of the mouse
brain, with long invasive extensions into the brain parenchyma. The corresponding vector cells
exclusively formed smaller ventricular and leptomeningeal metastases, with only sparse
micrometastases observed in the parenchyma. Because these observations were made using
the H&E stained brain sections harvested from mice that had become moribund, they represent
different time points and are not directly comparable; a repeat of the experiment could be
performed with all animals sacrificed at a set time point. Likewise, as this data represents overt
brain metastases, a repeated experiment could include the sacrifice groups of mice at early
times post-injection to investigate whether PCTK1 is more important for cancer cell survival at
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the early stages of dissemination, extravasation, and colonization or only once the tumors are
actively growing in the brain.
Out of curiosity as to whether PCTK1’s effect on brain metastasis was brain-specific or
common to all tumor growth in vivo, the relative abilities of 231.PCTK1 and 231.vector to form
primary mammary tumors in nude mice was assayed. While the experiment is still ongoing, as
of this writing there are no significant differences in primary tumor formation due to PCTK1
overexpression, suggesting its pro-growth effect may be metastasis-specific. However, in order
to test whether the phenotype is brain metastasis-specific, additional in vivo experimental
metastasis assays would be required to test whether PCTK1 enhances lung, bone, or even liver
metastasis in the MDA-MB-231 model.
When PCTK1 failed to show growth advantages in vitro, it was unsurprising due to its
status as a non-canonical CDK. However, it also failed to enhance migration, which is one of
its commonly reported phenotypes in myoblasts and neurons (212, 236, 237). Interestingly,
PCTK1 overexpression significantly reduced invasion of MDA-MB-231 cells through Matrigel,
which is especially striking in light of its enhancement of invasion through hard agar. Matrigel,
which is produced by a specialized line of mouse sarcoma cells, consists of a variety of
basement membrane proteins including laminin and Type IV collagen (238). The fact that
PCTK1 overexpression actually decreases invasion through Matrigel could simply be an in vitro
artifact due to the specific composition of Matrigel; after all, the same cells actually have a
growth advantage in the stiff matrix of hard agar and extend projections into the brain
parenchyma from the meninges in vivo. Alternatively, it may indicate antagonistic pleiotropy of
PCTK1 expression: if expressed in the primary tumor, it may actually decrease invasion through
the basement membrane and extravasation. This would be suggestive of the fact that PCTK1’s
functional benefit to metastases is limited to growth and survival at the metastatic site.
Experiments involving the modulation of PCTK1 in a spontaneous brain metastasis system
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such as HIM (239) or BBM (235) could be helpful in identifying whether PCTK1 truly inhibits
invasion and intravasation in vivo.
Because of the brain’s abundant supply of glutamine relative to other amino acids (194)
and the literature reports of brain metastatic tumor cells metabolizing glutamine to obtain ATP
and biomass (200), TCGA data was examined for potential correlations of PCTK1 expression
with glutamine metabolism. Since no large-scale datasets of brain metastasis are available,
PCTK1 expressional correlations were examined in primary breast cancer as well as primary
brain tumors, with the rationale that the brain environment represents a set of constraints, and
all tumors, both primary and metastatic, are subject to these rules. While there were some
correlations of PCTK1 with glutamine metabolism in all 3 subtypes of primary breast cancer
(with ASNS) and in glioblastoma (with glucosamine-fructose-6-phosphate transaminase 1,
GFPT1). The majority of the strong correlations observed were in low-grade glioma, where
correlations existed between PCTK1, ASNS, GLS, and GLS2, as well and PCTK1, CDK5, and
CDK5R1. It is established that the BBB is intact in LGG (240), while the vascular permeability
of GBM renders the BBB functionally irrelevant (241). Therefore, the presence of these
underlying relationships in LGG is highly suggestive of the fact that glutamine metabolism is
important for cancer cell survival in the unique nutrient environment of the brain, but once the
BBB functional barrier is lost, the nutrient restriction is lifted and PCTK1 may no longer provide
a growth advantage.
The strength of the correlations between PCTK1 and the glutamine metabolism pathway
were intriguing enough to demand functional examination. Using BME, low glucose, low amino
acid-containing media, the PCTK1-overexpressing cells and their controls were compared for
their relative growth ability. The answer was clear: with PCTK1 overexpression, cells can
survive in glutamine-supplemented BME; without either glutamine presence of PCTK1
expression, the cells died. Attempts to grow the cells in similar concentrations of glutamate
instead of glutamine did not enable cell proliferation or survival, suggesting that if the cancer
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cells in the brain are involved in a glutamate-glutamine cycle, it is unlikely to be autocrine in
nature. Since one of the crucial functions of astrocytes in the brain is to scavenge glutamate
from the synapse, process it into glutamine, and deliver glutamine to neurons (242), the
potential exists that cancer cells, which are known to interact with astrocytes, use this same
pathway to obtain glutamine.
While the proliferative advantage enjoyed by PCTK1-overexpressing cells cultured in
glutamine pointed to the cells’ utilization of glutamine for energy or biomass generation, it could
simply be donating its amino group for purine biosynthesis and leaving the cell as glutamate
(243). Thus it was necessary to test whether there was a difference in glutamine and glutamate
uptake and release from cell culture media by cancer cells. Indeed, MS analysis showed that
although not statistically significant, glutamine uptake is slightly enhanced by PCTK1
overexpression. At the same time, net glutamate release into the media is actually lower in
PCTK1-overexpressing cells. The combined increase in glutamine uptake and decrease in net
glutamate release implies that the glutamine is being used as a fuel or mass substrate, although
further MS experiments tracing the fate of glutamine’s carbons and nitrogens are necessary
are necessary to confirm whether they are being used for energy or building blocks.
In order to test whether there was a functional requirement for PCTK1 in brain
metastasis, the HCC1954Br cell line was selected. A HER2-overexpressing line, 1954Br forms
large parenchymal brain metastasis lesions in nude mice. Furthermore, of all of the in vivo
brain-selected cell lines in the lab, it had the highest endogenous expression of PCTK1.
Therefore, when knockdown of PCTK1 extended the median survival of 1954Br-bearing mice
by nearly 60%, it was quite striking. The fact that the brain H&E sections of 1954Br controls
and PCTK1-knockdown cells appeared to be morphologically very similar, in spite of their
differences in survival time, could indicate two possibilities. Either the PCTK1 expression
recovered in vivo, either through loss of the shRNA plasmid or selection for a clone that had
inefficient knockdown, or PCTK1 provides a growth advantage at the early stage of brain
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colonization but is dispensable later. While IHC analysis of the same slides for PCTK1
expression did reveal that PCTK1 expression can recover in vivo in the shRNA knockdown
group, the expression of PCTK1 in all samples was heterogeneous. Therefore, the possibility
still remains that there is spatiotemporal variability in the requirement for PCTK1 during the
process of brain metastasis. To resolve the absolute necessity of PCTK1 and whether it is
important only at certain stages of the brain metastatic process, experiments utilizing CRISPRCas9-based knockout of PCTK1 of inducible shRNA against PCTK1 can be performed in vivo.

Conclusions and future directions
Brain metastasis is a common and deadly malignancy for which the biomedical research
has little in the way of understanding and even less in terms of treatment options. This study,
an in vivo functional genomics screen aimed at identification of novel kinases driving brain
metastasis, sought to better elucidate the biology of brain metastasis. The screen was
successful in identifying 31 potential drivers of brain metastasis, most of which are indeed
expressed in human brain metastases. The screen identified several hits related to glucose
utilization in the brain, a pathway already identified in brain metastasis that serves as a positive
control that this study’s underlying methodology was sound. Other interconnected networks
identified by the screen included calcium signaling, which is of great importance to neural
function but whose function in brain metastasis remains unclear, and the non-canonical CDK
axis of CDK5R1-CDK5-PCTK1. I validated the functional importance of PCTK1 in enhancing
brain metastasis growth by overexpression in the MDA-MB-231 model, and went on to show
that PCTK1’s brain metastasis growth enhancement does not extend to primary tumors in the
same model. Additionally, while PCTK1 did not convey proliferative or survival advantages in
vitro under normal culture conditions, it did dramatically enhance these phenotypes in a
glutamine-dependent manner when grown in a glucose and amino acid-limited medium that
was supplemented with glutamine to mimic the nutrient environment of the brain. Finally, I
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showed that stable knockdown of PCTK1 in a different breast cancer cell line delayed the
mortality due to brain metastasis by nearly 60%.
Future directions of this study will aim at identification of the molecular mechanism by
which PCTK1 enables the enhanced utilization of glutamine. By performing MS tracing analysis
of metabolites generated from isotopically labeled glutamine, it will be possible to identify
exactly how brain metastatic cells may be utilizing glutamine, whether it be for fuel or
biomolecule generation. Identification of metabolites will guide the search for a direct
phosphorylation target of PCTK1, and identification of that PCTK1 substrate and its
phosphorylation site, followed by validation of the pathway’s activation in clinical brain
metastasis, could allow for the development of PCTK1-targeted therapy. Further studies
involving inducible knockdowns of PCTK1 can also be performed to investigate the timing of
PCTK1’s growth advantage in brain metastasis, and whether it is limited to the early
colonization steps or throughout brain metastatic growth. Additionally, CRISPR-based knockout
of PCTK1 will allow observation of whether PCTK1 is necessary for brain metastasis growth,
as it would remove the possibility of selection for metastatic clones with inefficient knockdown
of PCTK1.
Furthermore, there are 30 additional unvalidated targets that have been identified by
this study. While PCTK1 demonstrated a dramatic pro-brain metastasis phenotype, there could
be several other, potentially more important kinases and pathways to investigate in brain
metastasis. By using functional genomics, it was possible to identify the key barriers that cancer
cells have to overcome for growth in the brain. The potential exists that re-establishing these
barriers and forcing brain metastases into an evolutionary double bind could result in
therapeutic efficacy heretofore unseen in this disease setting.
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